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Simple Summary: Environmental and occupational exposure to heavy metals are risk factors for
cancers. However, the molecular mechanisms of how heavy metals induce carcinogenesis are still not
clear. In recent years, more and more studies have shown that abnormal epigenetic modifications are
involved in metal-induced cancers. In this review, we summarize the up-to-date understanding of
the contributions of epigenetic mechanisms to heavy metal-induced carcinogenesis and angiogenesis.
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Abstract: Environmental and occupational exposure to heavy metals, such as hexavalent chromium,
nickel, and cadmium, are major health concerns worldwide. Some heavy metals are well-documented
human carcinogens. Multiple mechanisms, including DNA damage, dysregulated gene expression,
and aberrant cancer-related signaling, have been shown to contribute to metal-induced carcinogenesis. However, the molecular mechanisms accounting for heavy metal-induced carcinogenesis and
angiogenesis are still not fully understood. In recent years, an increasing number of studies have
indicated that in addition to genotoxicity and genetic mutations, epigenetic mechanisms play critical
roles in metal-induced cancers. Epigenetics refers to the reversible modification of genomes without
changing DNA sequences; epigenetic modifications generally involve DNA methylation, histone
modification, chromatin remodeling, and non-coding RNAs. Epigenetic regulation is essential for
maintaining normal gene expression patterns; the disruption of epigenetic modifications may lead to
altered cellular function and even malignant transformation. Therefore, aberrant epigenetic modifications are widely involved in metal-induced cancer formation, development, and angiogenesis.
Notably, the role of epigenetic mechanisms in heavy metal-induced carcinogenesis and angiogenesis
remains largely unknown, and further studies are urgently required. In this review, we highlight
the current advances in understanding the roles of epigenetic mechanisms in heavy metal-induced
carcinogenesis, cancer progression, and angiogenesis.
Keywords: heavy metal; epigenetics; DNA methylation; histone modification; non-coding RNA;
carcinogenesis; angiogenesis
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1. Introduction

iations.

Environmental and occupational exposure to heavy metals has long been recognized
as a global public health concern. The main routes of environmental exposure to heavy
metals include contaminated food, water, and air, affecting the health of millions of people
around the world [1]. However, some heavy metals are widely used in modern industries
due to their special physical and chemical properties; the wide industrial use may lead to
occupational exposure in workers. Heavy metal exposure may cause a broad range of toxic
effects in multiple organs, such as respiratory problems, gastrointestinal (GI) dysfunction,
kidney toxicity, skin lesions, and vascular damage [2]. Because heavy metals are nonbiodegradable and some show persistent effects even after termination of exposure, heavy
metal exposure can cause long-term health risks [3]. Among the common environmental
and industrial heavy metals, hexavalent chromium (Cr(VI)), nickel (Ni), and cadmium (Cd)
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are classified as Group 1 carcinogens by the International Agency for Research on Cancer
(IARC) [4]; exposure to them is strongly associated with increased risk of various types
of cancer, such as lung cancer, breast cancer, and GI cancers [2,5]. In vitro transformation
experiments and in vivo animal studies have provided solid evidence for their carcinogenic
ability in transforming normal cells into cancer cells and causing cancers in animals. Multiple mechanisms have been discovered to contribute to heavy metal-induced carcinogenesis,
including oxidative stress, DNA damage and repair, and abnormal signaling transduction [6]. In recent years, alterations of epigenetic modulations, such as DNA methylations,
histone modifications, and non-coding RNAs, have also been shown to contribute to metal
carcinogen-induced cell transformation [7]. In this review, we summarize the most up-todate knowledge on the involvement of epigenetic mechanisms and non-coding RNAs in
carcinogenic metal-induced tumorigenesis and angiogenesis.
1.1. Epigenetic Mechanisms
Epigenetics refers to dynamic and heritable modifications to the chromatin without alterations in the genomic sequence; epigenetic regulations represent important mechanisms
in regulating gene expression. Epigenetic modifications of the genome commonly include
DNA and RNA methylations, histone modifications, and non-coding RNAs. These modifications regulate gene expression by altering the local structural dynamics of chromatin,
primarily regulating its accessibility and compactness [8]. Compared to genomic alterations,
epigenetic alterations are usually reversible and more quickly regulated. A large number of
studies have shown that cancer cells harbor extensive “epigenomic landscape” aberrations,
which may lead to global dysregulation of gene expression profiles [9]. The aberrant epigenetic alterations, alone or along with widespread genetic alterations, are widely involved in
cancer formation and development. In recent years, a large number of studies have shown
that epigenetic modifications are involved in metal-induced carcinogenesis. In this review,
we summarize the mechanisms of epigenetic modifications, including DNA methylation,
histone modifications, and non-coding RNAs, in tumorigenesis and angiogenesis caused
by heavy metal exposure.
1.1.1. DNA Methylation and Demethylation
DNA methylation is the most extensively studied epigenetic mechanism; it generally
refers to the covalent addition of methyl groups from S-adenosylmethionine (SAM) to the
5-position of the cytosine pyrimidine ring [10]. DNA methylation predominantly occurs in
short CpG-rich DNA domains, called CpG islands (CGIs), which are preferentially located
on the 50 end of genes [10]. DNA methylation and demethylation are dynamic processes,
which harbor a fundamental function in regulating gene expression. In general, DNA
methylation leads to gene silencing because the 5-methylcytosine structure can inhibit
transcriptional factors from binding to DNA and/or remodel chromatin to make it less
accessible [11]. DNA methylation is catalyzed by DNA methyltransferases (DNMTs), which
work cooperatively to transfer the methyl groups to the CGIs of chromatin. In contrast,
DNA demethylation generally results in the re-expression of silenced genes due to DNA
methylation [11] (Figure 1). Because of its fundamental role in regulating gene expression,
DNA methylation/demethylation is widely involved in various cellular functions and
processes, such as cell proliferation, cell cycle, apoptosis, migration, and invasion [12].
Therefore, the aberrant DNA methylation and demethylation dynamics have been shown
to contribute to a variety of human diseases and cancers [12]. For example, global DNA
hypomethylation may contribute significantly to the formation and development of cancers,
because it predisposes cells to genomic instability and further genetic errors [13]. In addition
to genome-wide hypomethylation, site-specific hyper- and hypomethylation have also
been implicated in cancer development by regulating the expression of oncogenes or
tumor suppressors [13]. For example, hypomethylation and increased expression of S100
calcium-binding protein A4 (S100A4) have been reported in colon cancer [14]. Silencing of
RUNX3 due to promoter hypermethylation occurred in esophageal cancer, leading to the
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colon cancer [14]. Silencing of RUNX3 due to promoter hypermethylation occurred in
esophageal cancer, leading to the inactivation of its downstream targets [15]. In recent
years, a large number of studies have shown that aberrant DNA methylation is involved
inactivation of its downstream targets [15]. In recent years, a large number of studies have
in metal-induced carcinogenesis.
shown that aberrant DNA methylation is involved in metal-induced carcinogenesis.

Figure 1. The schematic diagram of DNA methylation and demethylation mechanism.
Figure 1. The schematic diagram of DNA methylation and demethylation mechanism.
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genome-wide loss of H4-lysine 16 acetylation (H4K16ac) has been characterized as a comhistone methylation are closely associated with various human diseases and cancers. For
mon hallmark of human tumors [20]. Aberrant H3K9 and H3K27 methylation patterns are
example, genome-wide loss of H4-lysine 16 acetylation (H4K16ac) has been characterized
associated with various forms of cancer [21]. Additionally, the timeless circadian regulator
as a common hallmark of human tumors [20]. Aberrant H3K9 and H3K27 methylation
(TIMELESS) gene was transcriptionally activated by H3K27ac in colorectal cancer (CRC),
patterns are associated with various forms of cancer [21]. Additionally, the timeless circaand up-regulated TIMELESS promoted the proliferation, invasion, and metastasis of CRC
dian regulator (TIMELESS) gene was transcriptionally activated by H3K27ac in colorectal
both in vitro and in vivo [22]. In recent years, more and more studies have shown that
cancer (CRC), and up-regulated TIMELESS promoted the proliferation, invasion, and mehistone modifications are involved in metal-induced carcinogenesis.
tastasis of CRC both in vitro and in vivo [22]. In recent years, more and more studies have
shown
that histoneRNA
modifications are involved in metal-induced carcinogenesis.
1.1.3.
Non-Coding
The majority of the human genome is transcribed to RNAs that do not encode proteins,
named non-coding RNAs. Non-coding RNAs are mainly categorized according to their size
as small non-coding RNAs (< 200 nt) and long non-coding RNAs (lncRNAs, > 200 nt) [23].
Among non-coding RNAs, microRNA (miRNA), lncRNA, and circular RNA (circRNA)
have been shown to play important roles in regulating gene expression at transcriptional
or post-transcriptional levels; therefore, they are widely involved in the initiation and
progression of human malignancies [23]. In recent years, a growing number of studies
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have shown that non-coding RNAs are dysregulated in cells exposed to heavy metals and
play important roles in metal-induced carcinogenesis. In this review, we highlight the
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most recent understanding of the roles of non-coding RNAs, mainly miRNA, lncRNA, and
circRNAs, in carcinogenic metal-induced cancers.
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as cell proliferation and differentiation, apoptosis and cell cycle, cell metabolism, migraThis section summarizes the up-to-date studies on the involvement of epigenetic mechtion, and invasion [32]. Abnormal expression of lncRNAs is involved in all stages of cancer
anisms and non-coding RNAs in Cr(VI)-induced carcinogenesis and angiogenesis. Cr is a
development, including the formation, progression, and metastasis of cancer, by exerting
naturally occurring heavy metal widely distributed in soil, rocks, and living organisms. Cr
pro-oncogenic or tumor-suppressive roles [32]. For example, up-regulation of lncRNA
primarily exists in two stable valence states: trivalent chromium [Cr(III)] or Cr(VI) [35]. EnLINC00152 promoted the development of non-small cell lung cancer (NSCLC) through
vironmental Cr(VI) exposure is mainly through water, air, automobile exhaust, and tobacco
activating EGFR, which promoted tumor cell proliferation by increasing the activity of the
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consumption. Occupational exposure to Cr(VI) often occurs in industrial settings, such as
leather tanning, smelting, welding, stainless steel production, and pigment manufacturing;
the main routes of occupational Cr(VI) exposure are inhalation or dermal absorption [36].
In the blood, most Cr is bound to plasma proteins, particularly transferrin; only about 5% of
Cr is free [37]. Cr accumulates mainly in the liver, spleen, soft tissue, and bone in the human
body [38,39]. Cr is mainly excreted through the urinary system; therefore, urinary Cr level
serves as a good indicator of Cr absorption [40,41]. Environmental and occupational Cr(VI)
exposure have become major public health concerns. Cr(VI) exposure can cause a series of
adverse effects on the respiratory system (including asthma, bronchitis, and respiratory
tract irritation), skin (including contact dermatitis, skin burns, blisters, and skin ulcers),
gastrointestinal (GI) tract (including gastric ulcers and gastritis), and kidneys (acute tubular
necrosis and renal failure) [36]. Acute high-level Cr poisoning is often fatal; no proven
antidote is available and the treatments are usually supportive and symptomatic, such as
ventilatory support, cardiovascular support, and renal and hepatic function monitoring [42].
Orally administered ascorbic acid, chelating reagents, and exchange transfusion have been
tried for acute Cr intoxication; however, the currently available evidence is not sufficient
to support the application of these therapies in acute Cr poisoning [42]. For patients with
chronic low-dose Cr exposure, no specific treatment is needed and the patients should
avoid further exposure and rely on the urinary and fecal clearance of the accumulated Cr
in the body [42]. Cr(VI) compounds are also classified as Group 1 human carcinogens by
IARC [43]. As a potent human carcinogen, Cr(VI) exposure is associated with an increased
risk of lung cancer among occupationally exposed workers [44,45].
The carcinogenic effects of Cr(VI) have been mainly studied in lung cancers as the
lung is the major target of Cr(VI). Cr(VI) is well-known for its ability to transform normal
human lung epithelial cells, such as BEAS-2B and 16HBE cells; the transformed cells show
cancerous and cancer stem cell (CSC)-like properties [46]. Multiple mechanisms have
been identified to contribute to Cr(VI)-induced lung carcinogenesis, including oxidative
stress, DNA damage, abnormal signaling transduction, and inflammatory responses [47].
Although Cr(VI)-induced genotoxicity and mutagenicity are thought to be the primary
mechanisms of Cr(VI) carcinogenesis, an increasing number of studies have shown that
altered epigenetic modifications and dysregulation of non-coding RNAs contribute to
Cr(VI)-induced cell transformation and tumorigenesis in recent years.
2.1. DNA Methylation
As a major type of epigenetic modification, DNA methylation has been intensely
studied in the context of Cr(VI) exposure [48]. Fundamental alterations in DNA methylation
status have been discovered in the blood and lung cancer tissues of Cr(VI)-exposed workers
and in Cr(VI)-exposed and transformed lung epithelial cells [49]. Here, we summarize
the most recent understanding regarding the roles of DNA methylation in Cr(VI)-induced
tumorigenesis and angiogenesis.
Because DNA damage represents one of the major genotoxic effects of Cr(VI), some
studies have investigated the role of DNA methylation in Cr(VI)-caused DNA damage and
dysfunction of the DNA repair system. Cr(VI) exposure has been shown to cause increased
DNA damage and down-regulated expression of p16INK4a (a negative regulator of the cell
cycle) in 16HBE cells. The CpG1, CpG31, and CpG32 of p16INK4a were hypermethylated
and the methylation levels of these sites were negatively correlated with p16INK4a expression and cell survival rate but positively correlated with DNA damage level, suggesting
that increased methylation of p16INK4a may contribute to Cr(VI)-induced cancer by lowering p16INK4a expression and causing accumulation of DNA damage [50]. Furthermore,
reduced expression of p16INK4a and aberrantly up-regulated methylation of p16INK4a promoter were also discovered in human workers with lung cancer and long-term (≥15 years)
exposure to Cr(VI), suggesting that the hypermethylation of p16INK4a is involved in the
Cr(VI) carcinogenesis [51]. In another study, the methylation was increased for the CpG
sites in DNA repair genes, including O6-methylguanine-DNA-methyltransferase (MGMT),
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8-oxoguanine DNA glycosylase (HOGG1), RAD51 recombinase (RAD51), X-ray repair crosscomplementing 1 (XRCC1), and ERCC excision repair 3 (ERCC3). The mRNA levels of these
genes were decreased in Cr(VI)-exposed 16HBE cells; the methylation levels of these genes
were negatively correlated with corresponding mRNA levels [52]. In a cross-sectional study of
87 workers exposed to Cr and 30 subjects without Cr exposure, DNA damage was accumulated in Cr(VI)-exposed workers, and hypermethylation of the CpG sites of DNA repair genes,
including MGMT, HOGG1, and RAD51, was also observed in these workers [52]. These
studies indicate that DNA hypermethylation may suppress the DNA repair system, leading
to accumulated genetic damage and finally contributing to Cr(VI) carcinogenesis.
Lung cancers of Cr(VI)-exposed workers have a higher frequency of replication error
(RER) (defined by the presence of microsatellite instability (MSI)) than lung cancers of
patients not exposed to Cr(VI) [53,54]. MSI is often caused by the loss of DNA mismatch
repair (MMR) genes, such as MutL homolog 1 (MLH1) [55]. In the Cr(VI)-exposed lung
cancers, the MLH1 level was repressed and the down-regulated MLH1 expression was
correlated with the degree of MSI [54,56]. Increased methylation of MLH1 promoter was observed in Cr(VI)-exposed lung cancers, which was associated with repressed MLH1 expression [54,56,57]. Notably, the direct effect of MLH1 methylation on MLH1 protein expression
was not investigated by these studies. The overall methylation status was also significantly
higher in Cr(VI) lung cancers than non-Cr(VI) lung cancers [57]. Additionally, increased promoter methylation and decreased expression of p16 and APC were also observed in Cr(VI)exposed lung cancers [57]. These results suggest that DNA hypermethylation-mediated
down-regulation of MLH1 expression may contribute to Cr(VI)-induced carcinogenesis by
impairing the DNA repair system. The roles of aberrant DNA methylation/demethylation
in Cr(VI)-induced carcinogenesis and cancer progression are summarized in Table 1.
Table 1. Roles of altered DNA methylation in Cr(VI) exposure-induced carcinogenesis.
Cells or
Tissues

Compound

Route

Exposure
Time

16HBE cells [50]

Dichromate
(Cr2 O7 2− )

Culture
medium

24 h

Human lung
cancer [51]

Chromate

Inhalation

>15 y

16HBE/human
lung cancer [52]

Human lung
cancer [54,56]

Human lung
cancer [57]

Potassium
dichromate
(K2 Cr2 O7 )

Chromate

Chromate

Culture
medium/
inhalation

Inhalation

Inhalation

24 h

N/A

N/A

Change (s)
Hypermethylation at
CpG1, CpG31, and
CpG32 of p16INK4a
promoter

Hypermethylation of
MGMT, HOGG1,
RAD51, XRCC1, and
ERCC3

Hypermethylation of
MLH1 promoter

Global DNA
hypermethylation
Hypermethylation of
p16 and APC
promoters

Role

Prooncogenic

Mechanism
Hypermethylation of the
promoter caused lowered
p16INK4a expression and
accumulation of
DNA damage.

Prooncogenic

Decreased the expression
of these DNA repair genes,
leading to suppressed
DNA repair system and
resultant accumulation of
genetic damages.

Prooncogenic

Inhibit the expression of
MLH1, a DNA mismatch
repair gene, causing
increased microsatellite
instability of the genome.

Prooncogenic

Globally increased
genomic methylation;
increased promoter
methylation caused
decreased expression of
p16 and APC, two tumor
suppressors, contributing
to Cr(VI) carcinogenesis.

Cr(VI): hexavalent chromium; MGMT: O6-methylguanine-DNA-methyltransferase; HOGG1: 8-oxoguanine DNA
glycosylase; RAD51: RAD51 recombinase; XRCC1: X-ray repair cross-complementing 1; ERCC3: ERCC excision
repair 3; MLH1: MutL homolog 1; APC: adenomatous polyposis coli.
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2.2. Histone Modification
2.2.1. Histone Methylation
Histone modification is another common type of epigenetic modification involved
in the formation and development of cancers [16]. Cr(VI) exposure has been shown
to cause extensive alterations in histone modifications. For example, Cr(VI) exposure
caused globally increased levels of H3K9me2/3 and H3K4me2/3 but decreased levels of
H3K27me3 and H3R2me2 in A549 human lung cancer cells [58,59]. Cr(VI) also caused
gene-specific histone modifications that resulted in altered gene expression. For example,
Cr(VI) exposure induced increased H3K9me2 in the promoter of MLH1, likely through
up-regulating G9a (also known as euchromatic histone-lysine N-methyltransferase, 2),
a histone methyltransferase that specifically methylates H3K9, causing repressed MLH1
expression [58]. The altered global and gene-specific histone modifications and the resultant
gene expression changes, such as inhibition of tumor suppressor MLH1, have been shown
to contribute to Cr(VI) carcinogenesis in a growing number of studies.
Chronic low-dose Cr(VI) exposure has been shown to induce cell transformation
and acquisition of cancer stem cell (CSC)-like properties in BEAS-2B and 16HBE cells.
Cr(VI)-transformed cells had increased levels of H3K9me2 and H3K27me3, two repressive methylation marks, and greatly increased levels of histone-lysing methyltransferases
(HMTs) for H3K9 (GLP, G9a, SUV39H1 histone lysine methyltransferase (SUV39H1)) or
H3K27 (enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2)) [46]. Additionally, SUV39H1 and EZH2 were also up-regulated in the lung cancer of Cr(VI)-exposed
workers [46]. The up-regulated HMTs played a causal role in elevated levels of H3K9me2
and H3K27me3, and were indispensable in Cr(VI)-induced cell transformation and in
maintaining the cancerous and CSC-like property of Cr(VI)-transformed cells. Furthermore,
increased HMTs also contributed to Cr(VI)-exposure-caused DNA damage, as knockdown
of HMTs attenuated Cr(VI)-induced DNA damage. Collectively, these results indicate
that dysregulated histone modification machinery contributes to Cr(VI)-induced genotoxic
effects, carcinogenesis, and cancer progression [46].
Hedgehog (Hh) signaling plays a key role in embryogenesis and stem cell functions;
dysregulation of the Hh pathway has been reported in various human cancers. The
expression of the hedgehog-interacting protein (HHIP), a downstream target and a negative
regulator of Hh signaling, was down-regulated in Cr(VI)-transformed BEAS-2B cells and
primary lung cancers [60]. The down-regulation of HHIP contributed to Cr(VI)-induced
malignant transformation by activating the Hh signaling, as the forced expression of
HHIP inactivated Hh signaling and inhibited cell proliferation and anchorage-independent
growth in Cr(VI)-transformed cells [60]. Mechanistically, the suppressed HHIP expression
was attributed to multiple epigenetic modifications of its promoter region, including DNA
hypermethylation, reduced levels of H3K9ac and H3K4me3, two active histone marks, and
enriched H3K27me3, a repressive histone mark [60].
2.2.2. Histone Acetylation
Histone acetylation is another major type of histone modification. C-X-C motif
chemokine ligand 5 (CXCL5) is an inflammatory factor involved in multiple processes
relevant to tumor formation and progression [61]. CXCL5 level was dramatically upregulated in the peripheral blood monocytes (PBMCs) and plasma from workers with
occupational exposure to Cr(VI) and the lung tissues of mice intranasally exposed to
Cr(VI) and Cr(VI)-transformed BEAS-2B cells [62]. Functionally, CXCL5 promoted Cr(VI)induced cell transformation and played an important role in maintaining cancer phenotypes
of Cr(VI)-transformed BEAS-2B cells. CXCL5 also prompted Cr(VI)-induced epithelialmesenchymal transition (EMT) by up-regulating zinc finger E-box binding homeobox 1
(ZEB1) [62]. Two mechanisms have been proposed to account for the up-regulated CXCL5:
Cr(VI) exposure activated c-Myc, which specifically binds to the CXCL5 promoter and
recruited p300 to form a transcription complex; the c-Myc/p300 complex then enhanced
the histone H3 acetylation and eventually promoted CXCL5 transcription. Hypomethy-

Cancers 2022, 14, 5768

9 of 43

lation of CXCL5 promoter due to Cr(VI)-induced DNA methyltransferase 1 (DNMT1)
down-regulation also contributed to CXCL5 induction [62]. These findings indicate that
epigenetic machinery contributes to Cr(VI)-induced carcinogenesis and cancer progression
through epigenetically up-regulating CXCL5. The level of nuclear protein 1 (NUPR1) was
significantly up-regulated in Cr(VI)-exposed BEAS-2B cells due to epigenetic mechanisms,
such as hypomethylation and increased H3K9 and H3K14 acetylation levels of its promoter [63]. Elevated NUPR1, in turn, led to reduced global and promoter-specific H4K16ac
(such as for tripartite motif containing 42 (TRIM42) and inhibitors of apoptosis (IAP)) by
inhibiting the transcription of males absent on the first (MOF), a histone acetyltransferase
that specifically acetylates H4K16 [64]. Functionally, up-regulated NUPR1 promoted Cr(VI)induced transformation of BEAS-2B cells, consistent with previous reports that NUPR1
promoted the development and metastasis of lung, pancreatic, and breast cancers [65–67].
Notably, NUPR1 expression was not increased in transformed BEAS-2B cells, suggesting
that it may only be required for initiation of cell transformation; however, reduced MOF
and H4K16ac were observed in both Cr(VI)-exposed and transformed cells, indicating
that they were required for both initiation and maintenance of cell transformation [63].
These results support the notion that Cr(VI)-induced NUPR1 contributes to Cr(VI)-induced
carcinogenesis by altering the histone modification marks and subsequent gene expression
perturbations [63]. c-Myc is a master regulator of cell metabolism; dysregulated metabolism
plays an important role in cancer development [68]. Clementino et al. have found that
c-Myc mediated aberrant histone acetylation contributes to Cr(VI)-induced carcinogenesis
by promoting glycolytic shift [69]. Cr(VI)-transformed BEAS-2B cells showed glycolytic
shift mediated by up-regulated c-Myc. The glycolytic shift, in turn, led to increased acetyl
coenzyme A (acetyl-CoA) levels and several histone acetylation marks, including H3K9ac,
H3K27ac, and acetyl-histone 4 (Ac-H4) and 2B (Ac-H2B). The up-regulated acetylation of
H3 at the promoter of ATP citrate lyase (ACLY) promoted the transcription of ACLY, a key
enzyme for producing acetyl-CoA; up-regulated ACLY, in turn, increased c-Myc expression,
acetyl-CoA level, and histone acetylation, forming a positive feedback loop that drives a
metabolic shift in Cr(VI)-transformed cells [69]. The glycolytic shift and resultant glycolysis
played critical roles in maintaining the malignant phenotypes of Cr(VI)-transformed cells,
because the reverse of the glycolytic shift by glucose depletion significantly inhibited the
growth, CSC-like property, and tumorigenicity of the transformed cells [69]. SET nuclear
proto-oncogene (SET), a major regulator of histone modifications, was increased in Cr(VI)exposed and Cr(VI)-transformed 16HBE cells [70]. Increased SET promoted proliferation
and cell cycle progression and inhibited apoptosis of transformed 16HBE cells. Mechanistic
studies indicated that increased SET mediated the reduction in H3K18ac and H3K27ac at
the tumor protein P53 binding protein 1 (53BP1) promoter, resulting in decreased expression
of 53BP1 in Cr(VI)-exposed and Cr(VI)-transformed 16HBE cells [70,71]. The 53BP1 protein
binds to the central domain of TP53 and plays an important role in DNA damage repair [72];
inhibition of 53BP1 may cause DNA damage accumulation and inhibition of apoptosis,
therefore promoting tumorigenesis and cancer progression [73]. Additionally, Cr(VI) also
caused global decreases in H3K18ac and H3K27ac, which might have broad effects on
gene expression. These results demonstrate the involvement of SET-mediated histone
hypoacetylation in Cr(VI)-induced lung carcinogenesis. The roles of histone modifications
in Cr(VI)-induced carcinogenesis and cancer progression are summarized in Table 2.
2.3. Non-Coding RNA
2.3.1. miRNA
The dysregulation of miRNA expression has recently been shown to have important
roles in Cr(VI)-induced cell transformation, carcinogenesis, and angiogenesis. Speer et al.
reported that acute or prolonged exposure to Cr(VI) led to altered global miRNA expression
in the human bronchial fibroblast WTHBF-6 cell line. In silico pathway analysis revealed
these altered miRNAs were enriched in pathways involved in carcinogenesis [74]. Two
redox-sensitive miRNAs, miR-27a and miR-27b, were down-regulated in response to ROS
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production in BEAS-2B cells chronically exposed to Cr(VI), in Cr(VI)-transformed BEAS2B cells, and in the lung tissues of mouse intranasally exposed to Cr(VI) for 12 weeks.
The down-regulated miR27a/b promoted Cr(VI)-induced tumorigenesis and angiogenesis
through up-regulating NF-E2-related factor-2 (Nrf2) [75], a transcription factor that has
been known to promote cell proliferation, colony formation, migration, and angiogenesis
in various cancers [76]. These results indicate that miR-27a and miR-27b act as tumor
suppressors and the miR-27a/b/Nrf2 signaling plays a pivotal role in Cr(VI)-induced
carcinogenesis and angiogenesis.
Table 2. Roles of histone modifications in Cr(VI) exposure-induced carcinogenesis.
Cells or
Tissues

Compound

Route

Exposure
Time

BEAS2B/16HBE
cells [46]

K2 Cr2 O7

Culture
medium

20 w/40 w

Human
lung cancer
[57]

Chromate

Inhalation

NA

A549 [58]

K2 CrO4

Culture
medium

1 h–24 h

A549 [59]

K2 CrO4

Culture
medium

24 h

BEAS-2B
[60]

BEAS-2B
[62]

BEAS-2B
[63]

K2 CrO4

K2 Cr2 O7

K2 CrO4

Culture
medium

Culture
medium

Culture
medium

6 months

6 months

24 h/1–2 w

Modification (s)

Increased global
H3K9me2 and
H3K27me3

Globally increased
H3K9me2/3 and
H3K4me2/3, but
decreased
H3K27me3
and H3R2me2
Increased
H3K9me2 in MLH1
promoter

Reduced H3K9ac
and H3K4me3, but
enriched
H3K27me3 in the
promoter of HHIP

Enhanced histone
H3 acetylation in
the promoter of
CXCL5

Increased H3K9ac
and H3K14ac of
NUPR1 promoter

Role

Mechanism

Prooncogenic

Cr(VI) led to up-regulated global
H3K9me2 and H3K27me3 by
increasing the levels of HMTs. The
aberrant histone methylation
contributed to Cr(VI)-induced
genotoxicity and carcinogenesis.

Prooncogenic

Cr(VI) induced globally increased
H3K9me2/3 and H3K4me2/3, but
decreased H3K27me3 and
H3R2me2. Cr(VI) also caused
increased H3K9me2 in MLH1
promoter, likely via up-regulating
G9a and SUV39H1, causing
repressed expression of MLH1, a
tumor suppressor.

Prooncogenic

Cr(VI) caused reduced levels of
H3K9ac and H3K4me3 but
enriched H3K27me3 in the
promoter of HHIP, leading to
decreased expression of HHIP.
Decreased HHIP activated the
hedgehog signaling, which
contributed to Cr(VI)
carcinogenesis.

Prooncogenic

Cr(VI) activated the c-Myc/p300
complex, which was specifically
bound to the CXCL5 promoter
and enhanced H3 acetylation and
eventually promoted CXCL5
transcription. Up-regulated
CXCL5 contributed to Cr(VI)
carcinogenesis.

Prooncogenic

Cr(VI) caused increased H3K9ac
and H3K14ac of NUPR1 promoter
and elevated NUPR1 expression,
which in turn promoted
Cr(VI)-induced transformation
of BEAS-2B cells.
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Table 2. Cont.
Cells or
Tissues

BEAS-2B
cells [69]

16HBE
[70,71]

Compound

K2Cr2O7

K2 CrO4

Route

Culture
medium

Culture
medium

Exposure
Time

20 w

15 w

Modification (s)

Increased H3K9ac
and H3K27ac at the
promoter of ACLY

Global and 53BP1
promoter-specific
decreases in
H3K18ac and
H3K27ac

Role

Mechanism

Prooncogenic

Cr(VI) led to a glycolytic shift,
which led to increased H3K9ac,
H3K27ac, and H2B and H4
acetylation. The up-regulated
H3ac at the ACLY promoter
promoted ACLY transcription;
up-regulated ACLY in turn
increased the glycolytic shift and
histone acetylation, forming a
positive feedback loop. The
glycolytic shift played a critical
role in maintaining the malignant
phenotypes of
Cr(VI)-transformed cells.

Prooncogenic

Cr(VI) caused increased SET,
resulting in global and 53BP1
promoter-specific reduction in
H3K18ac and H3K27ac. The
promoter histone hypoacetylation
resulted in decreased expression
of 53BP1, which contributed to
Cr(VI) carcinogenesis by causing
DNA damage accumulation and
inhibition of apoptosis.

Cr(VI): hexavalent chromium; HMTs: histone-lysing methyltransferases; MLH1: MutL homolog 1; HHIP:
hedgehog-interacting protein; CXCL5: C-X-C motif chemokine ligand 5; NUPR1: nuclear protein 1; ACLY:
ATP citrate lyase; SET: SET nuclear proto-oncogene; 53BP1: P53 binding protein 1.

An oncogenic miRNA, miR-21, was up-regulated in Cr(VI)-treated BEAS-2B cells, and
elevated miR-21 promoted Cr(VI)-induced transformation of BEAS-2B cells. Mechanistically, Cr(VI) induced interleukin-6 (IL-6) expression, which in turn promoted the signal
transducer and activator of transcription 3 (STAT3) phosphorylation, and activated STAT3
bound to the miR-21 promoter to promote its transcription. Up-regulated miR-21 directly
down-regulated programmed cell death 4 (PDCD4), a tumor suppressor [77,78]; inhibition
of PDCD4 suppressed downstream E-cadherin expression and promoted β-catenin/TCFdependent transcription of c-Myc and plasminogen activator, urokinase receptor (uPAR).
The c-Myc oncogene plays a critical role in the process of carcinogenesis [79], and uPAR
is involved in cancer progression [80]. These results suggest that activation of the miR21/PDCD4 signaling contributes to Cr(VI)-induced lung carcinogenesis through regulating
important downstream factors, such as E-cadherin, c-Myc, and uPAR [77]. Additionally,
up-regulated miR-21 and suppressed PDCD4 were also observed in the lung tissues of
mice intranasally exposed to Cr(VI), multiple lung cancer cell lines (H2030, H460, H23,
and A549), and human lung adenocarcinoma tissues, suggesting that the miR-21/PDCD4
pathway is involved in lung cancer caused by both Cr(VI) and non-Cr(VI) factors [77].
Furthermore, quercetin, an antioxidant flavonoid widely present in fruits and vegetables,
inhibited Cr(VI)-induced activation of miR-21/PDCD4 cascade in BEAS-2B cells by decreasing ROS generation; quercetin therefore inhibited Cr(VI)-induced malignant transformation
and suppressed the growth of xenograft tumor of Cr(VI)-transformed cells, suggesting
a preventive and therapeutic role of quercetin in Cr(VI)-caused lung cancer [78]. On
the contrary, Cr(VI) caused the down-regulation of miR-21 in L02 hepatocytes, and the
subsequent increase in PDCD4 contributed to Cr(VI)-induced apoptosis and inhibited proliferation of L02 cells, suggesting that the inhibited miR-21/PDCD4 signaling contributes
to Cr(VI)-induced hepatotoxicity [81].
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Expression of miR-143, a tumor-suppressive miRNA [82], was decreased in BEAS-2B
cells exposed to Cr(VI), Cr(VI)-transformed BEAS-2B cells, and the plasma of Cr(VI)exposed workers [83,84]. Suppressed miR-143 promoted the growth and tumor angiogenesis of Cr(VI)-transformed BEAS-2B cells in vitro and in vivo [83,84]. Mechanistically,
ectopic miR-143 overexpression directly targeted both insulin-like growth factor-1 receptor
(IGF-IR) and insulin receptor substrate-1 (IRS1), suppressed the activation of downstream
ERK signaling, and inhibited the EKR pathway, lowering the expression of IL-8, a major
angiogenesis activator in Cr(VI)-induced angiogenesis [83]. miR-143 could also inhibit
the expression of IL-6, hypoxia-inducible factor-1 subunit alpha (HIF-1α), p70S6K1, and
NF-κB p65, causing reduced expression of IL-8 and vascular endothelial growth factor
(VEGF) [83,84]. Collectively, these results indicate that down-regulation of miR-143 contributes to Cr(VI)-induced carcinogenesis and angiogenesis through activation of multiple
signaling pathways, including IGF-IR/IRS1/ERK, mTOR/p70S6K1, HIF-1α/VEGF, and
NF-κB p65 pathways [83,84]. Moreover, the miR-143 level was also significantly lower in
A549 and H2195 lung cancer cells than in BEAS-2B cells, suggesting a broad role of miR-143
in lung cancer [83].
Cr(VI) exposure has been shown to cause DNA damage and subsequent activation of
DNA repair genes. In a cohort study, plasma miR-3940-5p level was significantly downregulated in workers exposed to Cr(VI) and negatively associated with blood Cr level.
However, the low miR-3940-5p level was associated with high expression of XRCC2 (a
DNA repair gene targeted by miR-3940-5p) in peripheral lymphocytes [85]. Furthermore,
miR-3940-5p was inhibited in Cr(VI)-treated 16HBE cells; down-regulated miR-3940-5p
then enhanced homologous recombination after double-strand breaks (DSBs) caused by
Cr(VI) exposure [86]. These studies suggest that repression of miR-3940-5p plays a protective role in Cr(VI)-induced cell transformation by mitigating the accumulation of DNA
damage. Exposure of human B lymphoblast HMy2.CIR cells to Cr(VI) caused global miRNA
expression changes. Functional analysis of altered miRNAs indicated that down-regulation
of miR-148a-3p and miR-21-5p might contribute to Cr (VI)-induced cell apoptosis, and
up-regulated miR-221-3p might result in increased cell apoptosis and accumulation of DSBs
and total DNA damage [87]. c-Myc, a proto-oncogene, played a critical role in maintaining
the CSC-like property and tumorigenicity of Cr(VI)-transformed BEAS-2B cells; it also promoted Cr(VI)-induced transformation and acquisition of CSC-like properties in BEAS-2B
cells. Mechanistic studies indicated that chronic Cr(VI) exposure increased c-Myc expression by down-regulating the level of miR-494, suggesting that inhibited miR-494/c-Myc
cascade contributes to chronic Cr(VI) exposure-induced initiation and progression of lung
cancer [88]. The roles of miRNAs in Cr(VI)-induced carcinogenesis and cancer progression
are summarized in Table 3.
Table 3. Roles of altered miRNA in Cr(VI) exposure-induced carcinogenesis.
Cells or
Tissues

Compound

Route

Culture
BEASNa2 Cr2 O7 / medium/
2B/BALB/
zinc
intranasal
cJ mice
chromate
instilla[75]
tion

Exposure
Time

6 months
/12 w

miRNA

miR-27a
miR-27b

Alteration

Down

Role

Tumor
suppressor

Target (s)

Mechanism

NRF2

MiR-27a/b were
down-regulated in
response to ROS
production upon Cr(VI)
exposure; down-regulated
miR27a/b promoted
Cr(VI)-induced
tumorigenesis and
angiogenesis by
up-regulating NRF2.
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Table 3. Cont.
Cells or
Tissues

BEAS-2B
[77,78]

L02 hepatocytes
[81]

BEAS-2B
[83,84]

Compound

K2 Cr2 O7

NA

Na2 Cr2 O7

Human
lung
cancer
[85]

Na2 Cr2 O7

16HBE
[86]

Na2 CrO4

BEAS-2B
[88]

K2 Cr2 O7

Route

Culture
medium

Culture
medium

Culture
medium

Inhalation

Culture
medium

Culture
medium

Exposure
Time

24 h/
6 months

24 h

6 months

3.0–10.0
years

miRNA

miR-21

miR-21

miR-143

miR-39405p

Alteration

Up

Down

Down

Down

Role

Oncogenic

Proapoptotic

Tumor
suppressor

Oncogenic

Target (s)

Mechanism

PDCD4

Cr(VI) promoted miR-21
transcription by activating
STAT3. Up-regulated
miR-21 directly targeted
PDCD4, a tumor
suppressor. Inhibition of
PDCD4 contributed to
Cr(VI)-induced cancer by
suppressing the
expression of E-cadherin,
c-Myc, and uPAR.

PDCD4

Cr(VI) caused a decrease
in miR-21 and a
subsequent increase in
PDCD4, contributing to
Cr(VI)-induced apoptosis
and decreased
proliferation of liver cells.

IGF-IR
IRS1

Cr(VI) lowered miR-143
expression; decreased
miR-143 promoted
Cr(VI)-induced tumor
growth and angiogenesis
by activating
IGF-IR/IRS1/ERK,
mTOR/p70S6K1,
HIF-1α/VEGF, and NF-κB
p65 pathways.

NA

24 h

20 w

miR-494

Down

Tumor
suppressor

c-Myc

Cr(VI) led to decreased
miR-3940-5p; the lowered
miR-3940-5p then
enhanced the HR of DSBs
to mitigate the
accumulation of DNA
damage, playing a
protective role in
Cr(VI)-caused cell
transformation.
Cr(VI) caused
down-regulation of
miR-494, which in turn led
to increased c-Myc,
contributing to
Cr(VI)-induced
transformation and
acquisition of CSC-like
properties in
BEAS-2B cells.

Cr(VI): hexavalent chromium; ROS: reactive oxygen species; Nrf2: NF-E2-related factor-2; PDCD4: programmed
cell death 4; uPAR: plasminogen activator, urokinase receptor; IGF-IR: insulin-like growth factor-1 receptor; IRS1:
insulin receptor substrate-1; HR: homologous recombination; DSBs: double-strand breaks; CSC: cancer stem cells.

2.3.2. lncRNA
Fewer studies have been performed to investigate the role of lncRNAs in Cr(VI)-induced
cancers. Hu et al. characterized the differentially expressed lncRNAs in 16HBE cells ex-
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posed to Cr(VI) for 24 h. They found 1868 significantly up-regulated and 2203 significantly
down-regulated lncRNAs. Further bioinformatics analysis suggested that the differentially
expressed lncRNAs formed a complex regulation network and were associated with immune
response, cell cycle, DNA damage, repair, etc. However, whether these dysregulated lncRNAs
contributed to Cr(VI)-induced carcinogenesis is currently unknown [89].
3. Nickel (Ni)
Ni is a ferromagnetic heavy metal widely distributed in the environment, such as soil,
air, and water. Ni has a variety of toxic effects upon environmental or occupational exposure.
Environmental exposure is mainly through contaminated soil, food, water, and air. Due to its
unique physical and chemical properties, Ni is widely used in modern metallurgical industries,
such as alloy production, electroplating, and battery production. Occupational exposure
generally occurs in these industrial settings, threatening the health of millions of workers
worldwide [90]. Ni can enter the human body through multiple routes, including inhalation,
ingestion with food or water, and dermal absorption, depending on the chemical form of the
pollutant [91]. Inhalation is the most common and riskiest route of exposure to Ni, which is
associated with an increased risk of lung cancer [92]. The inhaled Ni particles are deposited
in different locations of the respiratory system, depending on the diameter, solubility, and
quantity of the particles. Water-soluble Ni compounds are absorbed by the lungs and enter the
blood and finally are excreted by the kidneys. Insoluble Ni compounds stay in the respiratory
system for a much longer time, where they cause respiratory manifestations and even lung
cancer [90]. Exposure to Ni can cause a variety of toxic effects on human health, such as
contact dermatitis, allergy, asthma, cardiovascular dysfunction, kidney diseases, lung fibrosis,
and lung and nasal cancer, depending on the dose, length, and chemical properties of exposed
chemicals [93,94]. Topical corticosteroids and nonsteroidal creams can be applied to reduce
irritation and rashes; for severe allergic scenarios, oral corticosteroids and antihistamines can
be used [95]. Acute Ni poisoning can be treated with chelating reagents, the same as the
treatment of the poisoning of other heavy metals. Sodium diethyldithiocarbamate (Dithiocarb)
has been proved to be most effective, while other chelators, such as tetraethylthiuram, dpenicillamine, and dimercaprol, are less effective and therefore have limited therapeutic value
for Ni poisoning [96]. Ni compounds have also been classified as Group 1 carcinogens by
IARC [4,6]. Long-term exposure to Ni is known to cause multiple types of human cancers,
including lung and nasal cancers [97]. In the past decades, researchers have put a lot of effort
into revealing the molecular mechanisms of Ni carcinogenesis. A large number of studies have
shown that Ni has low mutagenic potential, and Ni acts predominantly through epigenetic
mechanisms including DNA methylation, histone modification, and non-coding RNAs to
cause cancers. This section reviews the up-to-date understanding of epigenetic mechanisms
in Ni-induced cancers.
3.1. Ni and DNA Methylation
An early study using the transgenic gpt+ G12 Chinese hamster cell line as a model
discovered that Ni could alter gene expression by enhancing DNA methylation and chromatin
condensation, rather than by mutagenic mechanisms [98,99]. In recent years, more and
more studies focus on epigenetic modifications in Ni-induced carcinogenesis. Silencing of
O-6-methylguanine-DNA MGMT was observed in Ni-transformed 16HBE cells. Epigenetic
modifications at the MGMT promoter, including DNA hypermethylation, reduced histone
H4 acetylation and H3K9ac (indicators of open chromatin and active transcription) and
up-regulated H3K9me2 (a marker of condensed and inactive chromatin), accounted for
the suppression of MGMT expression in Ni-transformed cells [100]. Additionally, DNMT1,
together with methyl-CpG-binding protein 2 (MECP2) and methylated DNA-binding domain
protein 2 (PRDM2), were recruited to the CpGs region of the MGMT promoter to maintain
the hypermethylation state [100]. These results suggest that impaired DNA repair caused by
multiple epigenetic modifications may contribute to Ni-induced malignant transformation.

Cancers 2022, 14, 5768

15 of 43

The acquisition of EMT has been shown to play an important role in diseases associated with Ni exposure, such as asthma, fibrosis, and lung cancer [101]. Similar to Arsenic
(As) and Cr(VI), Ni has also been shown to induce EMT in BEAS-2B cells by altering EMT
markers such as the up-regulation of fibronectin and down-regulation of E-cadherin [102].
Mechanistically, Ni inhibited E-cadherin expression by induction of ROS-dependent promoter hypermethylation of E-cadherin. These results suggest the involvement of epigenetic
induction of EMT in Ni carcinogenesis [102].
In a Ni-induced muscle tumor model in Wistar rats, the mRNA expressions of retinoic
acid receptor beta (RAR-β2), Ras association domain family member 1 (RASSF1A), and
cyclin-dependent kinase inhibitor 2A (CDKN2A) were decreased, and hypermethylation
of the 5’ region of these genes was found in the muscle tumors [103]. In a Ni-caused
malignant fibrous histiocytomas moue model, tumors had a down-regulated expression of
p16Ink4a and hypermethylation of its DNA, and activation of the MAPK signaling pathway
was observed, suggesting a role of synergistic interactions between MAPK activation
and p16Ink4a silence in Ni carcinogenesis [104]. Notably, neither the significance of the
aberrantly expressed genes nor the influence of hypermethylation on the expression of
these genes was investigated in these two studies. Bypassing senescence is a critical step in
the malignant transformation of mammalian cells. A study in primary dermal fibroblast
SHD cells indicated that epigenetic silencing of p16Ink4a by promoter DNA methylation
contributed to Ni-induced immortalization, suggesting epigenetic silencing of p16Ink4a
plays an important role in Ni carcinogenesis [105].
Activation of oncogenic genes through DNA hypomethylation is also involved in
Ni-elicited cancers. Angiopoietin-like protein 4 (ANGPTL4) is induced by hypoxia, and
its high expression is associated with progression and poor prognosis in several types of
cancers [106,107]. Kang et al. found that ANGPTL4 was up-regulated in Ni-treated BEAS-2B
and lung cancer cell lines [108]. Mechanistic studies indicated that Ni induced accumulation of HIF-1α, which mediated the transcriptional activation of ten-eleven translocation
methylcytosine dioxygenase 1 (TET1), a demethylase that mediates the first step toward DNA
demethylation by converting 5-mC into 5-hmC [109,110]. The up-regulated TET1 caused
hypomethylation of the ANGPTL4 promoter, resulting in up-regulated ANGPTL4 expression.
Because of the oncogenic property, up-regulated ANGPTL4 was supposed to contribute to
Ni-elicited carcinogenesis [110]. The roles of aberrant DNA methylation/demethylation in
Ni-induced carcinogenesis and cancer progression are summarized in Table 4.
Table 4. Roles of altered DNA methylation in Ni-induced carcinogenesis.
Cells or
Tissues

16HBE cells
[100]

BEAS-2B
cells [102]

Compound

Crystalline
NiS

NiCl2

Route

Culture
medium

Culture
medium

Exposure
Time

24 h

72 h/
6–9 d

Modification (s)

Hypermethylation of
MGMT promoter

Hypermethylation of
E-cadherin promoter

Role

Mechanism

Prooncogenic

MGMT was down-regulated
by DNA hypermethylation,
reduced histone H4-ac and
H3K9ac, and up-regulated
H3K9me2. Lowered
expression of MGMT
contributed to Ni-induced
malignant transformation.

Prooncogenic

Ni inhibited E-cadherin
expression by induction of
ROS-dependent promoter
hypermethylation, resulting
in the acquisition of EMT,
which contributed to Ni
carcinogenesis.
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Table 4. Cont.
Cells or
Tissues

Wistar rats
[103]

C57BL6
mice [104]

Dermal
fibroblasts
of Syrian
hamster
[105]

Compound

Ni3 S2

Ni3 S2

NiCl2

Route

Intramuscular
injection

Intramuscular
injection

Culture
medium

Exposure
Time

32 w

8 months

N/A

Modification (s)

Hypermethylation of
RAR-β2, RASSF1A,
and CDKN2A

Hypermethylation of
p16Ink4a

Hypermethylation of
p16Ink4a

Role

Mechanism

Unknown

Ni induced
hypermethylation of the 5’
region of RAR-β2, RASSF1A,
and CDKN2A, resulting in
decreased mRNA
expressions of these genes.

Prooncogenic

Ni induced
hypermethylation and
down-regulated expression
of p16Ink4a. The p16Ink4a
silence together with
activation of the MAPK
signaling may contribute to
Ni carcinogenesis.

Prooncogenic

Promoter
hypermethylation-induced
silencing of p16Ink4a
contributed to Ni-induced
immortalization of primary
dermal fibroblast SHD cells.

Ni: nickel; MGMT: O-6-methylguanine-DNA methyltransferase; ROS: reactive oxygen species; EMT: epithelial-tomesenchymal transition; RAR-β2: retinoic acid receptor beta; RASSF1A: Ras association domain family member 1;
CDKN2A: cyclin-dependent kinase inhibitor 2A.

3.2. Histone Modification
In recent years, a growing number of studies have indicated that multiple forms of
histone modifications are involved in Ni carcinogenesis by regulating the expression of cancer
genes and the activity of critical signaling pathways in cancer formation and development.
3.2.1. Histone Methylation
Histone methylation is an important epigenetic mechanism in regulating gene transcription. Ni induced extensive long-term transcriptional changes in BEAS-2B cells even
after the termination of exposure; meanwhile, genome-wide increases in H3K4me3 (an
activating histone modification) and H3K27me3 (a repressive histone modification) were
observed, suggesting that histone modifications are associated with Ni-induced extensive
gene expression [111]. H3K9me2 is a mark for gene silencing and is organized into large
repressive domains in close proximity to active genes [16,112]. Jose et al. showed that
Ni caused disrupted H3K9me2 domains and subsequent spreading of H3K9me2 into active chromatin regions likely through loss of CTCF-mediated insulation. The spreading
of H3K9me2 was associated with gene silencing. These results showed the effect of Ni
on H3K9me2 dynamics and the resultant chromatin domain disruption [112]. Exposure
of A549 cells to Ni led to significantly increased global levels of H3K9me2 [59,113] and
H3K4me3 [59,114]. Specifically, increased H3K4me3 was discovered in both the promoter
and coding regions of carbonic anhydrase 9 (CA9) and N-Myc downstream regulated
1 (NDRG1), which were the highest up-regulated genes in Ni-exposed A549 cells [114].
H3K27me3 is involved in Ni-induced EMT. Jose et al. indicated that Ni exposure induced
permanent EMT in BEAS-2B cells through irreversible activation of ZEB1, a master EMT
driver. Ni exposure led to a significantly decreased H3K27me3 level at the ZEB1 promoter
compared with untreated BEAS-2B cells. Because H3K27me3 is associated with transcriptional silencing of nearby genes, loss of H3K27me3 likely caused increased ZEB1 expression,
finally resulting in EMT in Ni-exposed cells [115]. In another study, Ni exposure caused
increased H3K9me2 levels at the sprouty RTK signaling antagonist 2 (SPRY2) promoter
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by inhibiting histone demethylase Jumonji domain containing 1A (JMJD1A), resulting
in repressed SPRY2 expression in BEAS-2B cells. SPRY2 is a negative regulator of ERK
signaling; repression of SPRY2 thus potentiated the Ni-induced ERK phosphorylation to
promote anchorage-independent growth. These results suggest that decreased expression
of SPRY2 by suppressive histone methylation may contribute to Ni carcinogenesis [116].
Iron- and 2-oxoglutarate-dependent dioxygenases are a broad family of non-heme
iron-containing enzymes that catalyze various important oxidative reactions in cells [117].
A key structural motif of these enzymes is a facial triad of 2-histidines-1-carboxylate that
coordinates the Fe(II) at the catalytic site [117]. JMJD1A is a member of this family of
dioxygenase and specifically demethylates H3K9me1/2 [118,119]. JMJD1A is a hypoxic
response gene that is induced by HIF-1α and involved in repressing the transcription of
target genes [118,119]. Abnormal expression of JMJD1A has been shown to contribute to
cancer formation and development [120]. Ni has been shown to inhibit JMJD1A and DNA
repair enzyme ABH2 (both belong to iron-dependent dioxygenase) by replacing the ferrous
iron in the catalytic centers. Given the functions of these two dioxygenases, inhibition of
them by Ni may cause widespread impacts on cells, such as impaired epigenetic profile and
DNA repair [121]. Ni induced histone demethylase JMJD1A expression in 786-0 renal cancer
cells and HEK293 cells; ascorbate could antagonize Ni-induced JMJD1A expression in these
cells by decreasing the stability of HIF-1α protein [122]. Guo et al. found that short-term Ni
exposure in HEK293T and 786-0 caused a reduced level of H3K27me3 and up-regulated the
expression of Jumanji domain-containing protein 3 (JMJD3), an H3K27me3 demethylase,
suggesting that increased JMJD3 accounts for the un-regulated H3K27me3 [123]. Chen
et al. showed that Ni exposure increased global H3K9me2 by inhibiting the demethylation
process, likely via decreasing the activity of a Fe(II)-2-oxoglutarate-dependent histone
H3K9 demethylase [124].
The LSD1 histone demethylase complex has been shown to repress gene transcription
by catalyzing the demethylation of H3K4me2, a mark for active transcription; Scm-like
with four mbt domains 1 (SFMBT1) is a “histone reader” subunit of the LSD1 complex [125].
Tang et al. found that exposure of A549 cells to Ni induced EMT; furthermore, the downregulated E-cadherin was caused by SFMBT1-mediated recruitment of LSD1 to E-cadherin
promoter and subsequent decrease in H3K4me2 levels of E-cadherin promoter, suggesting
the involvement of SFMBT1-LSD1-histone demethylation in the Ni-induced EMT [125].
Nicotinamide N-methyltransferase (NNMT) has been shown to decrease histone methylation by decreasing the cellular S-adenosylmethionine (SAM)/S-adenosylhomocysteine
(SAH) ratio [126]. Ni has been shown to induce H3K9me2 by inhibiting NNMT expression
to increase the cellular SAM/SAH ratio [127].
3.2.2. Histone Acetylation
Acetylation is another important type of modification to histone. Decreased histone
acetylation is associated with suppressed gene expression; therefore, it plays an important
role in tumorigenesis and development. Ni has been shown to cause reduced acetylation
of H2A, H2B, H3, and H4 in various cell lines, including A549, HAE, NRK, Hep3B, and
IGROV1 cells [113,128–130], and loss of histone acetylation was associated with marked
suppression of global gene transcription [128]. Further studies indicated that Ni inhibited
the acetylation of histone H4 through binding to the anchoring site on histidine-18 within
the NH2-terminal tail of H4 [129,131], causing conformational changes that implicated in
regulating gene transcription. Other mechanisms also contribute to Ni-induced chromatin
hypoacetylation. Ni induced histone hypoacetylation in Hep3B cells by inhibiting the
overall histone acetyltransferase (HAT) activity, a process dependent on Ni-induced ROS
production [132]. Histone hypoacetylation has been shown to play important roles in
regulating cell cycle progression and apoptosis, two hallmarks of cancer. Ni exposure
caused cell growth inhibition and apoptosis and significantly reduced Bcl-2 expression in
Hep3B cells. A global decrease in histone acetylation and reduced histone H4 acetylation
in the Bcl-2 promoter region was also observed. The decreased histone acetylation status
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contributed to Ni-caused apoptosis and Bcl-2 down-regulation, indicating that histone
hypomethylation may be involved in Ni carcinogenesis through regulating critical genes
and cellular processes in cancer [133]. Zhang et al. investigated the effect of enhanced
histone acetylation on Ni-induced cell transformation by treating different cells with histone
deacetylase inhibitor trichostatin A (TSA). TSA inhibited the ability of Ni to transform
both human osteoblastic TE 85 cells and mouse embryo fibroblast PW cells. TSA was also
able to reverse the cancer phenotypes of Ni-transformed cells. However, TSA had little
or no effect on established A549 and H460 cancer cell lines in terms of forming colonies
in soft agar, suggesting that the reversal effect of TSA is specific to Ni-transformed cells.
These results also indicate that augmented histone acetylation has an inhibitory effect on
Ni carcinogenesis and suggest the role of histone deacetylase inhibitors in preventing and
treating Ni-caused cancers [134].
Ni has also been shown to regulate histone phosphorylation. Ke et al. found that
Ni could induce phosphorylation of histone H3 at its serine 10 residue (H3S10) in A549
and BEAS-2B cells through activating the c-Jun N-terminal kinase (JNK)/stress-activated
protein kinase (SAPK) signaling pathway [135]. H3S10 phosphorylation has been shown
to facilitate cellular malignant transformation and participate in fundamental cellular
functions in various human cancers [136]. For example, STAT3 activated the NFAT signaling
by promoting histone H3S10 phosphorylation in the promoter of the nuclear factor of
activated T cells 2 (NFATC2) in gastric carcinogenesis [137]. Therefore, alterations in H3S10
phosphorylation might contribute to the carcinogenesis caused by Ni, a notion that needs
to be examined in future studies.
Ni induced substantial increases in the ubiquitination of H2A and H2B (uH2A and
uH2B) in various cell lines likely through inhibiting the activities of histone deubiquitinating
enzymes [113,138,139]. Ni has also been shown to cleave histone H2A [140,141] and H2B [142].
However, the influence of Ni-induced histone ubiquitination and cleavage on gene expression
and carcinogenesis needs to be investigated further. The roles of histone modifications in
Ni-induced carcinogenesis and cancer progression are summarized in Table 5.
Table 5. Roles of altered histone modifications in Ni exposure-induced carcinogenesis.
Cells or
Tissues
BEAS-2B
cells [111]

BEAS-2B
[112]

Compound

Route

NiCl2

Culture
medium

NiCl2

A549 cells
[59]

K2 CrO4

A549 [113]

NiCl2

A549 [114]

NiCl2

BEAS-2B
[115]

NiCl2

Culture
medium

Culture
medium

Culture
medium

Exposure
Time

Modification
(s)

Role

Mechanism

6w

Global
increases in
H3K4me3 and
H3K27me3

Unknown

Ni caused genome-wide increases in
H3K4me3 and H3K27me3, but the
role of these changes was unknown.

72 h

Global
H3K9me2
spreading

Unknown

Ni caused disrupted H3K9me2 (a
repressive mark) domains and
subsequent spreading of H3K9me2
into active chromatin regions, causing
global gene silencing.

24 h

Global increase
in H3K9me2
and H3K4me3
Increased
H3K4me3 of
CA9 and
NDRG1

Unknown

Ni led to increased global levels of
H3K9me2 and H3K4me3. Increased
H3K4me3 was also discovered in the
promoter and coding regions of CA9
and NDRG1, which were
up-regulated in Ni-exposed A549 cells.

72 h/6 w

Decreased
H3K27me3 at
the ZEB1
promoter

Prooncogenic

Ni led to decreased H3K27me3 (a
repressive mark) level at the ZEB1
promoter; loss of H3K27me3 likely
caused increased ZEB1 expression,
finally resulting in EMT in
Ni-exposed cells.
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Table 5. Cont.
Cells or
Tissues

BEAS-2B
[116]

HEK293T/7860 cells
[123]

HEK293/A549
cells [125]

16HBE [100]

Hep3B cells
[132]

Compound

NiCl2

NiCl2

NiCl2

Crystalline
NiS

NiCl2

Route

Culture
medium

Culture
medium

Culture
medium

Culture
medium

Culture
medium

Hep3B [133]

A549 [135]

Exposure
Time

24 h/8 w

NiCl2

Increased
H3K9me2 at the
SPRY2
promoter

24 h

Reduced
H3K27me3
level

48 h

Decreased
H3K4me2 of
E-cadherin
promoter

24 h

Reduced H4ac
and H3K9ac
and
up-regulated
H3K9me2 of
MGMT

2–24 h

12–48 h
Culture
medium

Modification
(s)

24–48 h

Global histone
hypoacetylation
Reduced H4ac
in Bcl-2
promoter
Increased
H3S10 phosphorylation

Role

Mechanism

Prooncogenic

Ni caused increased H3K9me2 at the
SPRY2 promoter by inhibiting
JMJD1A, resulting in repressed SPRY2
expression. SPRY2 is a negative
regulator of ERK signaling; repression
of SPRY2 thus activated the ERK
signaling to promote Ni
carcinogenesis.

Unknown

Ni caused a reduced level of
H3K27me3, possibly caused by
up-regulated JMJD3, an H3K27me3
demethylase, but the function of
decreased H3K27me3
was not studied.

Prooncogenic

Ni caused recruitment of LSD1
complex to E-cadherin promoter to
catalyze the reduction in H3K4me2
modification of E-cadherin promoter,
resulting in down-regulated E-cadherin
level and induction of EMT.

Prooncogenic

MGMT was down-regulated by DNA
hypermethylation, reduced histone
H4ac, and H3K9ac and up-regulated
H3K9me2. Lowered expression of
MGMT led to impaired DNA
repairing machinery.

Tumor
suppressive

Ni induced histone hypoacetylation
by inhibiting the overall HAT activity.
Ni also led to reduced H4 acetylation
in the Bcl-2 promoter, resulting in
Bcl-2 down-regulation, which
contributed to Ni-caused cell growth
inhibition and apoptosis.

Unknown

Ni induce phosphorylation of H3S10
by activating the JNK/SAPK signaling
pathway, but the role of H3S10
phosphorylation was not studied.

Ni: nickel; CA9: carbonic anhydrase 9; NDRG1: N-Myc downstream regulated 1; ZEB1: zinc finger E-box
binding homeobox 1; EMT: epithelial-to-mesenchymal transition; SPRY2: sprouty RTK signaling antagonist 2;
JMJD1A: Jumanji domain-containing protein 1A; LSD1: lysine-specific demethylase 1; MGMT: O-6-methylguanineDNA methyltransferase; HAT: histone acetyltransferase; JNK: c-Jun N-terminal kinase; SAPK: stress-activated
protein kinase.

3.3. Non-Coding RNA
3.3.1. miRNA
In recent years, more and more miRNAs have been identified to play a caustic role in
Ni-induced cancers. For example, Wu et al. have shown that miR-4417 plays an oncogenic
role in Ni-induced lung cancer. They found that miR-4417 was significantly up-regulated
in BEAS-2B and A549 cells exposed to Ni, and induction of miR-4417 contributed to the
Ni-induced tumorigenesis through targeting TGF-beta activated kinase 1 (MAP3K7) binding protein 2 (TAB2) [143]. In a study by Zhu et al., the expression level of miR-31 was
down-regulated in Ni-transformed BEAS-2B cells due to transcriptional repression by
RUNX family transcription factor-2 (RUNX2). Inhibition of miR-31 resulted in the acqui-
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sition of cancer hallmarks in BEAS-2B cells, such as increased colony-forming ability in
soft agar assay and enhanced migration and invasion abilities, whereas overexpression
of miR-31 repressed these cancer hallmarks in Ni-transformed cells [144]. Further studies indicated that down-regulation of miR-31 resulted in increased expression of SATB
homeobox 2 (SATB2) [144], which is a direct target of miR-31 and an important mediator of Ni-induced cell transformation [145]. These results indicate that activation of the
RUNX2/miR-31/SATB2 cascade contributes to Ni-mediated lung cancers. In a human
cohort study including 76 never-smoking lung cancer patients, higher miR-21 levels were associated with Ni exposure. Patients with high nickel/miR-21 levels had significantly shorter
overall survival (OS) and relapse-free survival (RFS) periods compared with those with low
Ni/miR-21 levels [146]. Mechanistically, Ni exposure induced miR-21 expression via activating the EGFR/NF-κB signaling pathway; up-regulated miR-21, in turn, suppressed the
expression of two miR-21 target genes, SPRY2 and reversion-inducing cysteine-rich protein
with kazal motifs (RECK), and promoted invasiveness of lung cancer cells [146]. Zhang
et al. established a Ni-induced muscle tumor model by injecting Ni3 S2 compounds into
Wistar rats. The expression of miR-222 was significantly up-regulated in the muscle tumor
tissues, while the expression levels of two target genes of miR-222, cyclin-dependent kinase
inhibitor 1B (CDKN1B) and CDKN1C, were down-regulated in the tumors [147]. They also
found that in Ni-transformed 16HBE cells, miR-222 was up-regulated with a concomitant
decrease in the expression of CDKN1B and CDKN1C. Given the tumor-suppressive roles
of CDKN1B and CDKN1C, miR-222-mediated down-regulation of CDKN1B and CDKN1C
may contribute to Ni-induced tumorigenesis or tumor progression [147].
The cross-talk between DNA methylation and miRNA expression has been shown
to contribute to Ni-induced carcinogenesis. Zhang et al. have shown that the downregulation of miR-203 in Ni-transformed 16HBE cells is likely due to hypermethylation
of the CpGs in the miR-203 promoter and first exon region [148]. Additionally, miR-203
has been shown to suppress Ni tumorigenesis by negatively regulating its target gene
ABL proto-oncogene 1 (ABL1), suggesting that DNA methylation-mediated silencing of
tumor-suppressive miRNAs contributes to Ni-induced cancer [148]. Ji et al. have shown
that in Ni-transformed 16HBE cells, the expression of miR-152 was down-regulated due to
promoter DNA hypermethylation; inhibition of miR-152 expression significantly promoted
cell growth in both parental and transformed 16HBE cells. Moreover, inhibition of miR-152
in 16HBE cells resulted in increased expression of DNMT1, which increased the methylation
of the miR-152 promoter, demonstrating a feedback loop between miR-152 and the DNMT1
to further promote Ni-induced cell malignant transformation [149].
Dysregulated miRNAs are also implicated in Ni-caused metabolism shifts. He et al.
have shown that Ni exposure caused a significant accumulation of HIF-1α in Neuro-2a,
a mouse neuroblast cell line. Up-regulated HIF-1α, in turn, promoted the transcription
of miR-210, and the elevated miR-210 modulated the energy metabolism shift to aerobic glycolysis after Ni exposure through inhibiting iron–sulfur cluster assembly proteins
(ISCU1/2) [150]. ISCU1/2 mediates the assembly of ISCs, the prosthetic groups critical for
enzymes that are responsible for mitochondrial respiration and energy production [151,152].
Therefore, the suppression of ISCU1/2 by miR-210 led to the inactivation of ISC-containing
enzymes and ultimately inhibited mitochondrial respiration [150]. Given that enhanced
aerobic glycolysis is a hallmark of cancer [153], the miR-210-mediated energy metabolism
shift upon Ni exposure may contribute to Ni-induced carcinogenesis. Notably, this HIF1α/miR-210/ISCU1/2/energy metabolism regulatory axis has been reported in different
cell types [154,155], including BEAS-2B cells [156]. Additionally, melatonin could attenuate
the Ni-induced increment in aerobic glycolysis in BEAS-2B cells through ROS scavenging
and subsequent suppression of this regulatory axis [156]. Saquib et al. have shown that in
HepG2 cells exposed to Ni nanoparticles, the expression of miR-210 was up-regulated, but
the function of elevated miR-210 was not investigated [157]. The roles of altered miRNAs
in Ni-induced cancers are summarized in Table 6.
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Table 6. Roles of altered miRNA in Ni exposure-induced carcinogenesis.
Cells or
Tissues
BEAS-2B
A549 cells
[143]

BEAS-2B
[144]

H1355/
H23 cells
[146]

Wistar
rats [147]

16HBE
[148]

16HBE
[149]

Neuro-2a
cells [150]

Compound

NiCl2

NiSO4

NiCl2

Ni3 S2

Crystalline
Ni3 S2

Route

Exposure
Time

Culture
medium

15
min–72 h

Culture
medium

Culture
medium

4w

24 h

Intramuscular
injection

32 w

Culture
medium

13 rounds
of chronic
exposure

Crystalline
NiS

Culture
medium

NiCl2

Culture
medium

NA

miRNA

miR-4417

miR-31

miR-21

miR-222

miR-203

miR-152

NiCl2

Culture
medium

Up

Down

Up

Role

Oncogenic

Tumor
suppressor

Oncogenic

Up

Oncogenic

Down

Tumor
suppressor

Down

Tumor
suppressor

Target (s)

Mechanism

TAB2

Activation of
miR-4417/TAB2 was
involved in Ni-induced
EMT and carcinogenesis.

SATB2

RUNX2 transcriptionally
inhibited miR-31, leading
to up-regulation of SATB2
to contribute to
Ni-induced BEAS-2B cell
transformation.

SPRY2
RECK

Activation of the
EGFR/NF-κB signaling
pathway upon Ni
exposure induced miR-21,
resulting in
down-regulation of SPRY
2 and RECK to promote
the invasiveness of lung
cancer cells.

CDKN1B
CDKN1C

In muscle tumors and
lung cancer, miR-222
mediated the
down-regulation of
CDKN1B and CDKN1C,
which contributed to
Ni-induced
tumorigenesis.

ABL1

Down-regulation of
miR-203 resulted in the
up-regulation of ABL1,
contributing to
Ni-induced cancer.

DNMT1

Inhibition of miR-152
resulted in increased
expression of DNMT1,
which promotes
Ni-induced cell growth
and malignant
transformation.

ISCU1/2

Up-regulated HIF-1α
promoted the
transcription of miR-210;
the elevated miR-210
modulates the energy
metabolism shift to
aerobic glycolysis through
targeting ISCU1/2.

2–8 h
miR-210

BEAS-2B
[156]

Alteration

24 h

Up

Oncogenic

Ni: nickel; TAB2: TGF-beta activated kinase 1 (MAP3K7) binding protein 2; SATB2: special AT-rich sequencebinding protein 2; SPRY2: sprouty RTK signaling antagonist 2; RECK: reversion-inducing cysteine-rich protein
with kazal motifs; CDKN1B: cyclin-dependent kinase inhibitor 1B; ABL1: ABL proto-oncogene 1; ISCU1/2:
iron–sulfur cluster assembly proteins.
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3.3.2. LncRNA
Reduced expression of lncRNA maternally expressed gene 3 (MEG3), a tumor-suppressive
lncRNA, has been reported in multiple cancers [158]. In BEAS-2B cells exposed to Ni,
MEG3 was also significantly down-regulated, which has been shown to contribute to the Niinduced malignant transformation of BEAS-2B cells [158]. Mechanistically, Ni-induced downregulation of MEG3 was attributed to promoter hypermethylation mediated by Ni-mediated
DNMT3b overexpression, and suppression of MEG3 consequently decreased interaction of
MEG3 with c-Jun, an inhibitory transcription factor for PH domain and leucine-rich repeat
protein phosphatase 1 (PHLPP1), causing c-Jun-mediated PHLPP1 transcriptional inhibition.
PHLPP1 suppression, in turn, activated the Akt/p70S6K/S6 axis to up-regulate HIF-1α protein translation, resulting in the malignant transformation of BEAS-2B cells [158]. These results
highlight the role of the cross-talk between epigenetic modifications and non-coding RNAs in
Ni-induced lung tumorigenesis.
4. Cadmium (Cd)
Cd and its compounds ubiquitously exist in the environment, food, drinking water,
and contaminated occupational workplaces, such as factories for producing batteries and
color pigments [159]. Tobacco smoking is also an important source of Cd exposure [160]. In
the blood, the majority of Cd is bound to carrier proteins, such as albumin and metallothionein. Cd can be taken up by the liver, where Cd induces the production of metallothionein
and causes hepatocyte necrosis and apoptosis. The main organ for long-term Cd accumulation is the kidney [161]. Urinary excretion represents the major mechanism of Cd
elimination from the body, although it is very slow. Due to slow excretion, Cd can accumulate in animals and plants with an exceptionally long half-life (about 25–30 years),
causing Cd contamination to continue to be a major public health concern for decades
even when the exposure is terminated. Cd exposure may result in damage and dysfunction in multiple organ systems, such as the skeleton, kidney, digestive, and respiratory
systems. For example, Cd has been shown to cause skeletal system demineralization
and Itai-Itai disease, with bone pain, physical impairment, and even bone fractures [162].
As Cd predominantly accumulates in the kidney long-term exposures to Cd can cause
renal dysfunction, such as proteinuria, aminoaciduria, and decreased glomerular filtration
rate [163]. Cd also presents toxicity to the cardiovascular system [164] and the reproductive
system [165]. The treatments for the intoxication of Cd mainly include using chelating
agents, such as ethylenediaminetetraacetic acid (EDTA), penicillamine (DPA), dimercaprol,
and dithiocarbamates. Plasma exchange can also be used for Cd poisoning in emergency
situations [166]. In 1993, Cd and its compounds were classified as Group 1 carcinogens by
IARC according to the evidence from both human and experimental animal studies [4,6].
Cd exposure is associated with an increased risk of thyroid cancer, prostate cancer, breast
cancer, bladder cancer, and lung cancer [167]. Cd has various cellular effects, such as
impacting cell proliferation, apoptosis, and metabolism, and it may affect all stages of
the carcinogenic process, including formation, progression, metastasis, and treatment response [168]. Studies have revealed some of the mechanisms of Cd-induced carcinogenesis,
including the induction of oxidative stress, inhibited DNA repair machinery, aberrant
gene expression, and perturbation of key signaling pathways involved in cancers [168,169].
Notably, although Cd is a well-established human carcinogen, the mechanisms by which it
induces cancer are still poorly understood.
Cd is also a carcinogen with low affinity to DNA and low mutagenicity, suggesting
that it may exert a tumorigenic effect through non-genotoxic ways [168]. In recent years,
epigenetic mechanisms and non-coding RNAs have been shown to play important roles
in Cd carcinogenesis. This section summarizes how epigenetic changes and non-coding
RNAs are involved in Cd-induced carcinogenesis and angiogenesis. Unlike studies in Cr
that largely focus on lung cancer, research on Cd-induced cancer is carried out in various
types of cancer.
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4.1. DNA Methylation
More and more studies have shown that Cd is able to modify DNA methylation status,
causing both global and gene-specific chromatic hypermethylation and/or hypomethylation. A series of studies support that these alterations in DNA methylation and subsequent
down-regulation of gene expression are involved in Cd carcinogenesis. Chronic exposure
to low-dose Cd caused a low apoptosis rate, increased DNA DSBs, and caused global
CpG island hyper- or hypomethylation in the liver of rats [170]. Cd exposure also led to
reduced expression of caspase-8 due to promoter hypermethylation, leading to decreased
hepatic apoptosis and increased preneoplastic lesions, evidenced by increased expression
of cytokeratin 8/18 (a marker of liver preneoplastic lesions) [170]. Prolonged exposure
to low-dose Cd resulted in the transformation of TRL 1215 liver cells, showing cancerous
phenotypes such as hyperproliferation, high invasiveness, and decreased serum dependence in transformed cells [171–173]. The transformed cells exhibited significant increases
in DNA methylation and DNA methyltransferase activity [171]. They also acquired high
invasiveness, partially through down-regulation of apolipoprotein E (ApoE), an established suppressor of cell invasion, during malignant transformation, as re-expression of
ApoE clearly abrogated the cell invasion in Cd-transformed cells [174]. The suppression
of ApoE has been attributed to hypermethylation of the regulatory region of the ApoE
promoter and Cd-mediated epigenetic suppression of liver X receptor α (LXRα), a transcriptional regulator for ApoE [174,175]. Down-modulation of TET1, a DNA demethylase
in response to Cd-induced oxidative stress, might also cause down-regulation of ApoE via
hypermethylation of the ApoE promoter [173].
Cd has been shown to act as a metalloestrogenic carcinogen and be associated with
breast carcinogenesis [176–178], and aberrant epigenetic modifications are involved in
Cd-induced breast cancers. Benbrahim-Tallaa et al. showed that chronic exposure to
low-dose Cd led to the transformation of the immortalized human breast epithelial cell
line MCF-10A, with the acquisition of typical cancer phenotypes, such as loss of contact
inhibition, increased colony formation, and ability to form xenograft tumors in mice. The
transformed cells displayed characteristics of basal-like breast carcinoma and harbored
global DNA hypomethylation and c-Myc and K-Ras overexpression [176]. Liang et al.
investigated the differential epigenome and transcriptome caused by Cd in MCF-7 breast
cancer cells. They identified 997 Cd-induced differential genes potentially regulated by
epigenetic mechanisms, and 400 of them were further validated in a large-scale breast
cancer cohort, among which thioredoxin reductase 1 (TXNRD1) and chaperonin-containing
TCP1 subunit 3 (CCT3) were identified as the critical genes that might play an important
role in Cd-induced carcinogenesis [179]. Bioinformatics analyses also suggested that the
epigenetically regulated differential genes were involved in important signaling pathways,
such as Wnt signaling, metabolism, and MAPK signaling [179].
Most errors occurring during DNA replication can be corrected by the proofreading
functions of DNA polymerase or by the post-replication MMR system. Inactivation of both
error-proof systems by mutations and epigenetic changes may lead to the accumulation of
a large number of mutations in cells and finally cause cancer [180]. Therefore, identifying
epigenetic factors that inactivate the mutation-avoidance system has important implications
for understanding the mechanisms for Cd-induced carcinogenesis. During Cd-induced
malignant transformation of 16HBE cells, global DNA methylation was progressively
increased, accompanied by progressively reduced expression of four DNA repair genes
(mutS homolog 2 (hMSH2), ERCC1, XRCC1, and hOGG1) and the accumulation of DNA
damage. Furthermore, the increased DNA methylation was associated with the overexpression of DNMT1 and DNMT3a; the reduced expression of hMSH2, ERCC1, XRCC1, and
hOGG1 was likely caused by heavily methylated promoter regions of these genes. These
results suggest that promoter hypermethylation-induced silencing of the DNA repair genes
represents a potential mechanism underlying Cd-mediated carcinogenesis [181]. Cartularo
et al. found that MGMT was epigenetically silenced in Cd-transformed BEAS-2B clones,
which were more sensitive to an alkylating agent, temozolomide [182].

Cancers 2022, 14, 5768

24 of 43

Hypermethylation-induced down-regulation of tumor suppressors has been shown to
result in tumorigenesis and cancer development. During the malignant transformation of
prostate epithelial RWPE-1 cells by Cd, a progressive increase in global DNA methylation
associated with the overexpression of DNMT3b was observed. Meanwhile, the expression
of two tumor-suppressor genes, RASSF1A and p16, was markedly reduced likely due to
hypermethylation of the promoter regions [183]. Cd treatment promoted the growth of
uveal and cutaneous melanoma cells due to the markedly reduced expression of p16INK4A
and caspase-8 in the uveal and cutaneous melanoma cells, respectively. The silencing of
p16INK4A and caspase-8 was attributed to hypermethylation induced by the increased
activity of DNMTs [184]. Chronic low-dose Cd exposure has been shown to enhance lymphoblast proliferation in vitro and in vivo [185,186]. One mechanism for this phenomenon
involved epigenetic silencing of tumor-suppressor gene p16. Yuan et al. showed that
chronic low-dose Cd stimulated human B lymphoblast HMy2.CIR cell proliferation by
down-regulating p16 via hypermethylation of CpG island in its promoter, suggesting
epigenetic silencing of p16 contributed to Cd-induced carcinogenesis [187]. These studies
indicate that genomic hypermethylation-induced quiescence of tumor suppressors may
contribute to Cd-induced cancers.
Conversely, several studies have shown that Cd could induce global DNA hypomethylation. Huang et al. showed that Cd stimulated K562 lymphoblast proliferation and
induced global DNA hypomethylation. The reduced global DNA methylation potentially
contributed to Cd-stimulated K562 cell proliferation, because methionine, a donator of
the methyl group in DNA methylation, was shown to prevent Cd-induced global DNA
hypomethylation and Cd-stimulated cell proliferation [188]. Pelch et al. investigated the
mRNA expression level and the promoter methylation status of five key genes relevant to
the carcinogenic process (including S100 calcium-binding protein P (S100P), hyaluronidase
1 (HYAL1), neurotrimin (NTM), nestin (NES), aldehyde dehydrogenase 1 family member
A1 (ALDH1A1)) in RWPE-1 cells malignantly transformed by Cd or As. Expressions of
HYAL1 (hyaluronan degradation) and S100P (cancer aggressiveness) were up-regulated in
transformed cells, correlated with hypomethylation of the chromatin near the transcriptional start sites of the two genes. In contrast, expressions of both NTM (cell adhesion) and
NES (stem cell function) were decreased in the transformants, correlated with hypermethylation near the transcriptional start site. These results suggest that Cd- or As-induced
alterations in DNA methylation may contribute to metal carcinogenesis via regulating
the expression of important genes [189]. Cd exposure increased the viability of HepG2
and MCF7 cells. Cd also induced global DNA hypomethylation by lowering the levels
of DNMT1, DNMT3A, and DNMT3B. Specifically, Cd-mediated DNMT down-regulation
resulted in hypomethylation of the promoter of two known oncogenic methyltransferases,
protein arginine methyltransferase 5 (PRMT5) and EZH2 [190,191]. This allows the enrichment of the nuclear transcription factor Y subunit alpha (NFYA) and E2F transcription
factor-1 (E2F1), transcription factors in the PRMT5 and EZH2 promoters, respectively, to
induce the expression of PRMT5 and EZH2. Up-regulated PRMT5 and EZH2, in turn,
led to the increased global level of symmetric dimethylarginine (SDMA) and two crucial
repressive histone marks, H4R3me2 and H3K27me3, which potentially silenced tumor
suppressors through the remodeling of the chromatin. These results provide mechanistic
insights into the DNA hypomethylation in Cd-induced cell proliferation and potential
carcinogenesis [192]. The roles of aberrant DNA methylation/demethylation in Cd-induced
carcinogenesis and cancer progression are summarized in Table 7.
4.2. Histone Modification
During the Cd-induced transformation of cells, multiple types of histone modifications have been discovered, which may contribute to Cd carcinogenesis through different
mechanisms. For example, Liang et al. found that Cd-transformed BEAS-2B cells showed
marked down-regulation of H3K4me2 and H3K36me3 and up-regulation of H3K9acS10ph,
H4K5ac, H4K8ac, and H4K12ac histone modification marks [193]. The transformed cells
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also exhibited EMT and enhanced migration ability, while treatment of Cd-transformed
cells with C646, a potent histone acetyltransferase inhibitor, suppressed the expression
of mesenchymal marker genes and cell migration ability of these cells, suggesting that
Cd-induced aberrant histone hyperacetylation is involved in EMT and lung cell transformation [193]. Cd exposure significantly promoted the proliferation, migration, and invasion of
MCF-7 and T47-D breast cancer cells by inhibiting autophagy-related 5 (ATG5)-dependent
autophagic flux. Mechanistically, a Cd-induced decrease in acyl-CoA synthetase short-chain
family member 2 (ACSS2) expression inhibited ATG5 expression by reducing the level of
H3K27ac in the promoter region of ATG5 [194]. Somji et al. found that metallothionein 3
(MT-3) expression was induced in UROtsa human urothelial cells transformed by Cd or
As. H4 acetylation and methylation of H3K4, which are associated with transcriptional
activation [16,195], were increased in the MT-3 promoter in the Cd- or As-transformed cells,
while histone H3K9 and H3K27 methylation, which are associated with a transcriptionally
repressed state, were also up-regulated in transformed cells. The pattern of histone modifications indicated that the MT-3 promoter in transformed cells had a “transcription ready”
and “transcription repressed” bivalent chromatin structure compared with the parental
cells, which allowed the metal-responsive transformation factor-1 (MTF-1) binding to metal
response elements (MRE) of the MT-3 promoter more readily in the transformed cells to
up-regulate MT-3 expression; however, this process was restricted in parental UROtsa
cells [196]. Histone methylation, another type of histone modification, is also involved
in Cd carcinogenesis. In BEAS-2B cells, exposure to Cd for 24 h led to increased global
H3K4me3 and H3K9me2 by inhibiting the activities of H3K4 and H3K9 demethylases,
respectively. Additionally, global H3K4me3 and H3K9me2 were also significantly increased
at 4 weeks, whereas no significant change was observed from 8 to 20 weeks when the cells
were transformed, suggesting that increased global H3K4me3 and H3K9me2 are involved
in early events of Cd carcinogenesis [197]. The roles of histone modifications in Cd-induced
carcinogenesis and cancer progression are summarized in Table 8.
Table 7. Roles of altered DNA methylation in Cd-induced carcinogenesis.
Cells or Tissues

Wistar rats
C57BL/6 mice
[170]

Compound

Route

Exposure
Time

CdCl2

i.p. injection

4w

TRL 1215 cell
[171]

CdCl2

Culture
medium

24 h/
1–10 w

TRL 1215
[173,174]

CdCl2

Culture
medium

10 w

MCF-10A cell
[176]

CdCl2

Culture
medium

40 w

Modification (s)

Caspase-8 promoter
hypermethylation

Global DNA and
ApoE promoter
hypermethylation

Global DNA
hypomethylation

Role

Mechanism

Tumor
suppressive

Cd led to reduced caspase-8
due to promoter
hypermethylation, leading to
decreased hepatic apoptosis
and increased
preneoplastic lesions.

Pro-oncogenic

Cd caused global DNA
hypermethylation and
hypermethylation of ApoE
promoter, leading to lowered
ApoE expression. Lowered
TET1 mediated ApoE
promoter hypermethylation.

Unknown

Cd induced global DNA
hypomethylation and c-Myc
and K-Ras overexpression, but
neither their correlation nor the
role of global DNA
hypomethylation in
Cd-induced breast cancer
was studied.

Cancers 2022, 14, 5768

26 of 43

Table 7. Cont.
Cells or Tissues

16HBE [181]

RWPE-1 cell [183]

Multiple
melanoma cell
[184]

HMy2.CIR
lymphoblast cell
[187]

RWPE-1 cell [189]

HepG2
MCF7 cells [192]

Compound

CdCl2

CdCl2

Route

Culture
medium

Culture
medium

Exposure
Time

Chronic
exposure for
35 passages

Modification (s)

Global and hMSH2,
ERCC1, XRCC1,
and hOGG1
promoter
hypermethylation

10 w

Global and
RASSF1A and p16
promoter
hypermethylation

CdCl2

Culture
medium

48–72 h

p16INK4A and
caspase-8
hypermethylation

CdCl2

Culture
medium

48 h/
3 months

p16 promoter
hypermethylation

CdCl2

CdCl2

Culture
medium

Culture
medium

8w

24–48 h

Hypomethylation
of HYAL1 and
S100P;
hypermethylation
of NTM and NES

Global DNA
hypomethylation
Hypomethylation
of PRMT5 and
EZH2 promoters

Role

Mechanism

Pro-oncogenic

Cd induced global DNA
hypermethylation and
hypermethylated promoters
of DNA repair genes (hMSH2,
ERCC1, XRCC1, and hOGG1),
which caused reduced
expression of these genes and
thereby accumulation
of DNA damage.

Pro-oncogenic

Cd induced global DNA
hypermethylation and
hypermethylation of the
promoter of RASSF1A and
p16, which led to markedly
reduced expression of these
two tumor suppressors.

Pro-oncogenic

Cd induced silencing of
p16INK4A and caspase-8,
attributed to promoter
hypermethylation caused by
increased activity of DNMTs.

Pro-oncogenic

Cd caused the
down-regulation of p16 via
hypermethylation of the CpG
island in its promoter.

Pro-oncogenic

Expression of HYAL1 and
S100P was up-regulated likely
due to promoter
hypomethylation; expression
of NTM and NES was
decreased likely due to
promoter hypermethylation.
Aberrant expression of these
genes may contribute
to Cd carcinogenesis.

Pro-oncogenic

Cd induced global DNA
hypomethylation and
hypomethylation of PRMT5
and EZH2 promoters to induce
their transcription.
Up-regulated PRMT5 and
EZH2 in turn led to the
increased global level of
H4R3me2 and H3K27me3
(both repressive histone marks),
which potentially silenced
tumor suppressors through
remodeling the chromatin.

Cd: cadmium; i.p. injection: intraperitoneal injection; ApoE: apolipoprotein E; TET1: tet methylcytosine dioxygenase 1; hMSH2: mutS homolog 2; ERCC1: ERCC excision repair 1; XRCC1: X-ray repair cross-complementing
1; hOGG1: 8-oxoguanine DNA glycosylase; RASSF1A: Ras association domain family member 1; DNMT:
DNA methyltransferase; HYAL1: hyaluronidase 1; S100P: S100 calcium-binding protein P; NTM: neurotrimin;
NES: nestin; PRMT5: protein arginine methyltransferase 5; EZH2: enhancer of zeste 2 polycomb repressive
complex 2 subunit.
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Table 8. Roles of altered histone modifications in Cd-induced carcinogenesis.
Cells or
Tissues

BEAS-2B
cell [193]

MCF-7
T47-D cells
[194]

UROtsa cell
[196]

BEAS-2B
[197]

Compound

CdCl2

CdCl2

CdCl2

CdCl2

Route

Culture
medium

Culture
medium

Culture
medium

Culture
medium

Exposure
Time

20 passages

24–72 h

N/A

6–48 h/20 w

Modification (s)

Global alterations
of H3K4me2
H3K36me3
H3K9acS10ph
H4K5ac H4K8ac
H4K12ac

Decreased
H3K27ac in ATG5
promoter

Increased H4-ac
and methylation
of H3K4, H3K9,
and H3K27

Increased global
H3K4me3 and
H3K9me2

Role

Mechanism

Prooncogenic

Cd-transformed cells showed
markedly decreased H3K4me2
and H3K36me3 and
up-regulated H3K9acS10ph,
H4K5ac, H4K8ac, and H4K12ac
histone modifications. Inhibition
of histone acetyltransferase
activity led to suppressed cancer
phenotypes of transformed cells,
suggesting that histone
hyperacetylation is involved in
Cd carcinogenesis.

Prooncogenic

Cd caused decreased ACSS2
expression, resulting in lowered
ATG5 expression by reducing
the level of H3K27ac in the
ATG5 promoter. The resultant
inhibition of ATG5-dependent
autophagic flux contributed to
Cd carcinogenesis.

Prooncogenic

Cd or As caused increased H4
acetylation and H3K4
methylation (transcriptional
activation marks) and increased
H3K9 and H3K27 methylation
(transcriptional repression
marks) in the promoter of MT-3.
This “bivalent” histone
modifications status of MT-3
facilitated MTF-1 binding to
MT-3 promoter to activate its
transcription. Up-regulated
MT-3 in turn contributed
to Cd carcinogenesis.

Unknown

Cd exposure led to increased
global H3K4me3 and H3K9me2
at 24 h and 4 w by inhibiting the
activities of H3K4 and H3K9
demethylases, respectively.
However, global H3K4me3 and
H3K9me2 had no significant
change from 8 to 20 weeks,
suggesting that increased global
H3K4me3 and H3K9me2 are
involved in early events of Cd
carcinogenesis. However, the
exact role of this change
was not studied.

Cd: cadmium; ACSS2: acyl-CoA synthetase short-chain family member 2; ATG5: autophagy-related 5; MT-3:
metallothionein 3; MTF-1: metal-responsive transformation factor-1.

4.3. Non-Coding RNAs
4.3.1. miRNAs
A growing number of studies have shown that chronic exposure to Cd can cause
fundamental changes in miRNA expression, thus mediating alterations in tumor-associated
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biological processes and facilitating the malignant transformation of cells. Yang et al. found
that exposure to high-dose Cd resulted in cell viability reduction and apoptosis in IEC-6
intestinal epithelial cells. Cd exposure also caused global changes in miRNA expression,
including up-regulated miR-124-3p and miR-370-3p. Elevated miR-124-3p and miR-3703p, in turn, promoted Cd-induced apoptosis by directly targeting Bcl-2, a suppressor of
apoptosis [198]. In another study, Cd was shown to induce apoptosis and ferroptosis, a
type of programmed cell death dependent on iron, in PC12 rat pheochromocytoma cells.
The mechanistic study indicated that Cd exposure induced miR-34a-5p expression, and upregulated miR-34a-5p contributed to Cd-induced apoptosis and ferroptosis, likely through
directly targeting sirtuin 1 (Sirt1), as the down-regulation of miR-34a-5p mitigated the
apoptosis and ferroptosis caused by Cd. However, the role of down-regulated Sirt1 in
miR-34a-5p-mediated apoptosis and ferroptosis was not validated in this study [199]. In
BEAS-2B and BEP2D lung epithelial cells, Cd exposure resulted in the down-regulation
of miR-30e, causing up-regulated expression of snail family transcriptional repressor 1
(SNAIL1), a direct target of miR-30e, and resultant EMT induction. EMT has been shown to
play an important role in Cd-associated diseases such as fibrosis, COPD, and cancers [200].
Therefore, miR-30e down-regulation and the consequent activation in SNAIL1 expression
might contribute to Cd-induced cancer formation and development through induction
of EMT, although evidence is lacking for a causal relationship [201]. Additionally, Urani
et al. reported down-regulated miR-34a and miR-200a and up-regulated SNAIL1 was
induced by Cd in HepG2 cells [202]. Both miR-34a and miR-200a are known negative
regulators for EMT in tumors [203,204], and SNAIL1 is a master regulator of EMT [205];
therefore, these results suggest that Cd may cause liver cancer by inducing EMT. Exposure
to multiple metal carcinogens simultaneously is common in industrial settings. Shortterm treatment of BALB/3T3 mouse fibroblasts with a mixture of As, Pb, and Cd could
cause fundamental changes in miRNA expression patterns; many altered miRNAs were
involved in various cellular functions, such as miR-154, miR-379, miR-204, and miR133 [206]. Chronic exposure to the As-Cd-Pb mixture has been shown to induce malignant
transformation of BALB/3T3 cells and increase miR-222 expression. Elevated miR-222
directly down-regulated Rad51c expression and impaired homologous recombination of
DNA during the initiation stage of cell transformation, suggesting that miR-222 is an
initiator of Cd-induced carcinogenesis [207].
It has been well-known that higher levels of Cd can cause vascular toxicity by primarily
targeting endothelial cells. Angiogenesis is a critical step for tumor growth and metastasis.
However, the effect of Cd on tumor angiogenesis has been poorly studied. Current studies
indicate that Cd has a dose-dependent effect on tumor angiogenesis. Low doses (1 µM–10 µM)
of Cd have been shown to promote tumor angiogenesis [208–211] by activating PKB/Akt [212],
NF-κB [213], and MAPKs [210] signaling pathways, resulting in endothelial cell activation
and tumor angiogenesis [214]; high concentrations (>10 µM) of Cd may cause damage and
apoptosis of endothelial cells [210,215] and decrease tumor angiogenesis [210]. In a study
by Che et al., Cd was shown to induce cytotoxicity and promote the tube-formation ability
of primary human umbilical vein endothelial cells (HUVECs) by down-regulating miR-101.
Suppressed miR-101, in turn, induced COX2 expression and endoplasmic reticulum (ER)
stress; up-regulated COX2 and ER stress led to increased vascular endothelial growth factor
(VEGF) protein level, resulting in abnormal angiogenesis [216]. Notably, the roles of epigenetic
modifications and non-coding RNAs in mediating the effect of Cd on angiogenesis remain
largely unclear; further studies are necessarily needed. The roles of altered miRNAs in
Cd-caused cancers are summarized in Table 9.
4.3.2. LncRNA
In recent years, the contributions of lncRNAs in Cd carcinogenesis have been extensively investigated. Here, we summarize the up-to-date advances in studying the roles of
lncRNAs in Cd-mediated tumorigenesis.
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Table 9. Roles of altered miRNA in Cd-induced carcinogenesis.
Cells or
Tissues

IEC-6 cell
[198]

PC12 cell
[199]

BEAS-2B
BEP2D
cells
[201]

HepG2
[202]

Balb/c3T3
cell [207]

HUVEC
cell [216]

PC3
DU145
cells [217]

BEAS-2B
[218]

Compound

Route

CdCl2

Culture
medium

CdCl2

CdCl2

CdCl2

Mixture of
NaAsO2 ,
CdCl2 , and
Pb(C2 H3 O2 )2

CdCl2

CdCl2

CdCl2

Culture
medium

Culture
medium

Culture
medium

Culture
medium

Culture
medium

Culture
medium

Culture
medium

Exposure
Time

miRNA

6–24 h

miR-124-3p
miR-370-3p

24 h

1–24 h/
72 h

24 h

16 d

12–36 h

20 w

12–20 w

miR-34a-5p

miR-30e

miR-34a
miR-200a

miR-222

miR-101

miR-128-3p

miR-224-5p

Alteration

Up

Up

Down

Down

Up

Down

Down

Up

Role

Tumor
suppressor

Tumor
suppressor

Tumor
suppressor

Tumor
suppressor

Oncogenic

Antiangiogenic

Tumor
suppressor

Oncogenic

Target (s)

Mechanism

Bcl-2

Cd induced miR-124-3p
and miR-370-3p, which
promoted Cd-induced
apoptosis by targeting
Bcl-2.

Sirt1

Cd-induced miR-34a-5p
expression and
up-regulated miR-34a-5p
contributed to Cd-induced
apoptosis and ferroptosis
by targeting Sirt1.

SNAIL1

Down-regulated miR-30e
led to increased SNAIL1
expression, which
contributed to Cd-induced
cancer through the
induction of EMT.

SNAIL1

miR-34a and miR-200a
were down-regulated,
causing increased SNAIL1,
which contributed to
Cd-induced cancer by
inducing EMT.

Rad51c

Elevated miR-222
down-regulated Rad51c
expression and impaired
DNA homologous
recombination during the
initiation stage of cell
transformation.

COX-2

Suppressed miR-101
induced COX2 expression
and ER stress; up-regulated
COX2 and ER stress led to
increased VEGF protein
levels, resulting in
abnormal angiogenesis.

SLC7A11

Cd induced LncRNA
OIP5-AS1, which served as
an endogenous sponge of
miR-128-3p to up-regulate
the expression of SLC7A11,
thereby inhibiting
ferroptosis.

QKI

Circular RNA SHPRH was
down-regulated, leading to
up-regulated miR-224-5p
and resultant
down-regulation of QKI to
promote proliferation, EMT,
migration and invasion, and
anchorage-independent
growth of cells.
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Table 9. Cont.
Cells or
Tissues

T-47D
[219]

Compound

CdCl2

Route

Culture
medium

Exposure
Time

72 h

miRNA

miR-374c-5p

Alteration

Down

Role

Tumor
suppressor

Target (s)

Mechanism

GRM3

Cd exposure caused
reduced m6A modification
of pri-miRNA-374c,
resulting in miR-374c-5p
down-regulation.
Suppression of miR-374c-5p
in turn promotes
proliferation, migration,
and invasion of cells by
activating GRM3.

Cd: Cadmium; Sirt1: sirtuin 1; SNAIL1: snail family transcriptional repressor 1; EMT: epithelial-to-mesenchymal
transition; Rad51c: RAD51 paralog C; HUVEC: Human umbilical vein endothelial cells; COX-2: cyclooxygenase-2;
ER: endoplasmic reticulum; VEGF: vascular endothelial growth factor; SLC7A11: solute carrier family 7 member
11; QKI: QKI, KH domain containing RNA binding; GRM3: glutamate metabotropic receptor 3. HUVEC: human
umbilical vein endothelial cells.

Cell growth and apoptosis play important roles in cancer formation and development.
Some studies have indicated that lncRNAs contribute to Cd carcinogenesis by regulating
cell proliferation and apoptosis. Exposure to Cd is related to the increased occurrence
of prostate cancer, and workers occupationally exposed to Cd have a higher risk of mortality from prostate cancer [220,221]. Additionally, chronic exposure to Cd promoted the
malignant transformation of the normal prostate epithelial (PWR1E and RWPE1) cells,
suggesting a causative role of Cd in prostate cancer [222]. Long-term exposure of PC3 and
DU145 prostate cancer cells to low-dose Cd has been shown to promote cell growth and
induce resistance to ferroptosis in vitro and in vivo [217]. LncRNA OIP5-AS1 expression
was greatly up-regulated in Cd-exposed PC3 and DU145 cells; up-regulated OIP5-AS1
served as an endogenous sponge of miR-128-3p to up-regulate the expression of SLC7A11,
a direct target of miR-128-3p, thereby inhibiting ferroptosis [217]. LncRNA-MALAT1 expression was up-regulated in Cd-transformed 16HBE cells, the lung tissues of Cd-exposed
rats, and the blood of Cr-exposed workers; furthermore, the blood MALAT1 expression
had a positive correlation with urinary/blood Cd concentrations in the workers. Silencing
MALAT1 inhibited cell proliferation and cell cycle progression, migration, and invasion,
and induced apoptosis in Cd-transformed 16HBE cells. The expression of forkhead box
C2 (FOXC2), STAT3, BCL2-associated X, apoptosis regulator (BAX), EGFR, and TGF-β1
was reduced, but Bcl-2 was increased in MALAT1-depleted cells, Additionally, there were
positive correlations of MALAT1 with the expressions of target genes, such as STAT3,
BAX, and TGF-β1, in the lungs of Cd-exposed rats and the blood of Cd-exposed workers.
These results suggest that MALAT1 contributes to Cd-mediated carcinogenesis and tumor
progression by regulating key genes related to cell proliferation, apoptosis, migration, and
invasion [223].
Cd-induced carcinogenesis is partly due to the accumulation of DNA damage and
chromosomal aberrations. In recent years, lncRNAs have been shown to be involved in
modulating DNA damage and repair in Cd toxicology. The Cd-transformed 16HBE cells
had a large number of lncRNAs with altered expression levels [224,225]. Among the dysregulated lncRNAs, ENST00000414355 [224] and ENST00000446135 [225] were significantly
up-regulated in transformed 16HBE cells, the lung of Cd-exposed rats, and the blood of
Cd-exposed workers. Silencing of ENST00000414355 [224] and ENST00000446135 [225]
both reduced DNA damage and the expressions of DNA damage-related genes (ATM
serine/threonine kinase (ATM), ATR serine/threonine kinase (ATR), and ATR interacting
protein (ATRIP)) but increased the expressions of DNA repair-related genes (damagespecific DNA binding protein 1 (DDB1), DDB2, OGG1, ERCC1, MSH2, RAD50, XRCC1,
and BRCA1-associated RING domain 1 (BARD1)), suggesting that these two lncRNAs
contribute to Cd carcinogenesis by causing the accumulation of DNA damage and inhibiting DNA repair systems. Additionally, ENST00000446135 could directly regulate the
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transcription of MSH2, a DNA repair-related gene [225]. LncRNA MT1DP has been shown
to promote Cd-induced DNA damage response, genome instability, and DNA replication
stress, and it inhibits homologous recombination repair in HepG2 cells. Mechanically, ATR
was activated to enhance HIF-1α expression upon Cd exposure, which in turn promoted the
transcription level of MT1DP. Up-regulated MT1DP was then recruited on the chromatin
and bonded to SMARCAL1 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily a-like 1) to competitively inhibit the interaction of SMARCAL1
with the RPA complexes, finally leading to increased replication stress and DNA damage.
Therefore, MT1DP contributed to Cd carcinogenesis via regulating Cd-induced DNA damage and replication stress by inhibiting the recruitment of SMARCAL1 to chromatin [226].
Cd is a well-known lung carcinogen; long-term exposure to low dose Cd has been
shown to cause BEAS-2B cell malignant transformation and obtaining of cancer stem cell
(CSC)-like phenotypes [227,228]. MEG3, a tumor-suppressive lncRNA, was significantly
down-regulated in Cd-transformed BEAS-2B cells likely due to the increased methylation of
the differentially methylated region (DMR) upstream of the MEG3 transcription start site by
induction of DNMTs. The reduced expression of MEG3 promoted Cd-exposure-induced cell
transformation and acquisition of CSC-like properties. Forced expression of MEG3 could
reduce cell proliferation, cell cycle progression, and colony formation in soft agar assay;
cause resistance to Cd-induced apoptosis; and lower the number of colonies in the serumfree suspension culture assay, an indicator of the stemness of the cells. Further mechanistic
studies revealed that forced expression of MEG3 led to increased p21 levels, reduced Rb
phosphorylation, and B-cell lymphoma extra large (Bcl-xL) levels in Cd-exposed cells,
thus reducing cell cycle progression and apoptosis resistance. These findings suggest that
suppressed MEG3 expression contributes to Cd-induced cell transformation and acquisition
of CSC-like properties by promoting cell cycle progression and apoptosis resistance [227].
Lin et al. found significant up-regulation of an oncogenic lncRNA DUXAP10 in Cdtransformed cells, and that elevated DUXAP10 plays an important role in Cd-induced
cell transformation and CSC-like property; DUXAP10 depletion in Cd-transformed cells
resulted in significantly decreased stemness markers (including KLF transcription factor-4
(KLF4), KLF5, Nanog, and surface CD133) and suspension spheres number. Mechanistically,
Cd transformation led to an increased level of paired box 6 (PAX6), which transcriptionally
up-regulated the expression of DUXAP10. Elevated DUXAP10, in turn, activated the
hedgehog signaling pathway, which is essential in maintaining the CSC-like properties in
Cd-transformed cells, by increasing glioma-associated oncogene homolog 1 (GLI1) protein
stability [228]. The above-mentioned studies highlight the important roles of lncRNAs in
Cd exposure-induced tumorigenesis and CSC-like properties.
4.3.3. CircRNAs
CircRNA is a recently identified non-coding RNA type, usually more than 200 nt in
length. CircRNAs have a ringlike structure, unlike lncRNAs, which are linear. CircRNAs
are transcribed from exon, intron, or intergenic regions and folded into complicated second
structures [229]. CircRNAs have been shown to regulate gene expression through multiple
mechanisms. They can act as miRNA decoys to prevent miRNAs from binding to their
targets and protect the target transcripts from degradation [229]. They can interfere with
transcription factors to bind to promoters and thus regulate targeted gene expression [229].
They can also work as a scaffold to regulate protein-protein interactions and the related
downstream signaling pathways [230]. Recently, some studies showed that lncRNAs and
circRNAs also participate in the epigenetic modulation of chromatin to regulate gene expression [231]. A growing number of studies demonstrate that circRNAs act as either tumor
suppressors [232] or oncogenes [233] in cancer development. In recent years, an increasing
number of studies have shown that circRNA expression is disturbed upon exposure to
Cd and in Cd-transformed cells, and dysregulated circRNAs are involved in Cd-induced
cancers. For example, several studies have indicated that circRNAs are implicated in Cd
carcinogenesis via sponging microRNAs to regulate gene expression. Circ-SHPRH was
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down-regulated during Cd-induced transformation of BEAS-2B cells, and suppression
of circ-SHPRH played a promoting role in Cd-carcinogenesis; forced expression of circSHPRH inhibited cell proliferation, EMT, migration, invasion, and anchorage-independent
growth in transformed BEAS-2B cells and prevented the Cd-induced transformation of
BEAS-2B cells [218]. Mechanistically, circ-SHPRH functioned as a sponge of miR-224-5p;
suppressed circ-SHPRH led to up-regulated miR-224-5p and resultant down-regulation
of QKI (QKI, KH domain containing RNA binding), a direct target of miR-224-5p and a
tumor-suppressor protein known to prevent proliferation and EMT during the progression
of human cancers [234,235], promoting Cd-induced tumorigenesis [218]. CircSPAG16 was
also significantly down-regulated in Cd-transformed BEAS-2B cells; overexpression of circSPAG16 inhibited the hallmarks of cancer in Cd-transformed cells, such as cell proliferation,
migration, invasion, and anchorage-independent growth. CircSPAG16 overexpression also
prevented the Cd-induced transformation of BEAS-2B cells. Mechanistically, circSPAG16
inhibited Cd carcinogenesis by suppressing oncogenic phosphatidylinositol 4-phosphate
5-kinase type-1 α (PIP5K1α) via direct interaction; suppressed PIP5K1α led to the inactivation of Akt. Therefore, down-regulated circSPAG16 contributed to Cd-induced
carcinogenesis by promoting PIP5K1α-induced activation of Akt [236]. Another circRNA,
circPUS7, has been shown to be up-regulated during the Cd-induced transformation of
BEAS-2B cells; elevated circPUS7 contributed to Cd-induced transformation of BEAS-2B
cells by sponging miR-770, resulting in up-regulated K-Ras [237], an oncogene playing important roles in cell proliferation and transformation [238]. Furthermore, the knockdown of
circPUS7 in transformed BEAS-2B cells significantly attenuated cell proliferation, migration,
invasion, and anchorage-independent growth [237]. These results indicate that circPUS7
plays an important role in Cd-tumorigenesis and in maintaining the cancer phenotypes of
Cd-transformed cells. Unlike the functions in lung cancer, Cd has been shown to induce
apoptosis and inflammatory reactions in bovine mammary epithelial cells (BMECs) and in
mouse mammary glands [239]. Circ08409 was up-regulated in Cd-exposed cells; elevated
circ08409 promoted apoptosis and led to altered expression of a series of inflammatory
factors in BMECs through directly sponging miR-133a, a miRNA directly targeting TGFB2,
to up-regulate TGFB2, which modulates cell proliferation, apoptosis, and inflammation.
The data highlighted the importance of the circ08409/miR-133a/TGFB2 axis in mediating
the pro-apoptotic and pro-inflammatory effects of Cd in mammary tissues [239].
4.3.4. RNA N6-Methyladenosine (m6A) Modification
Epigenetic modifications of RNAs, including mRNA, miRNA, and lncRNA, represent
another layer of epigenetic regulation of gene expression [240]. The m6A modification is
the most common post-transcriptional modification of RNA molecules that regulates RNA
metabolism; more and more studies have indicated that m6A-mediated gene expression
is involved in the development of various cancers [241]. However, its role in metal carcinogenesis has rarely been investigated. Li et al. showed that the global level of mRNA
m6A modification was significantly decreased in Cd-transformed BEAS-2B cells, mediated
by Cd-induced up-regulation of alkB homolog 5, RNA demethylase (ALKBH5), an m6A
demethylase [242]. Furthermore, ALKBH5 promoted the proliferation, migration, invasion,
and anchorage-independent growth of transformed BEAS-2B cells by reducing the m6A
level of phosphatase and tensin homolog (PTEN) mRNA via demethylating m6A in PTEN
mRNA, resulting in its instability and the reduction in PTEN protein expression [242].
These results suggest that ALKBH5 promotes Cd-induced carcinogenesis by reducing
PTEN mRNA stability in an m6A-dependent manner [242]. In Cd-transformed SV-HUC-1
human uroepithelial cells, Cd caused global changes in mRNA and protein expression
and m6A-modified genes. The integrated analysis of the transcriptome, proteome, and
m6A profiles revealed that some of the shared genes were involved in DNA damage
stimulus, cell proliferation, and onset or progression of cancer; this suggests that m6A
modification-mediated post-transcriptional regulation may be involved in Cd-induced malignant transformation of uroepithelial cells [243]. In another study, Yue et al. showed that
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reduced m6A modification of miR-374c-5p contributed to Cd-induced progression of breast
cancer [219]. In T-47D and MCF-7 breast cancer cells, Cd exposure caused reduced m6A
modification of pri-miRNA-374c, resulting in miR-374c-5p down-regulation by decreasing
pri-miRNA-374c transcript stability. Suppression of miR-374c-5p, in turn, promoted proliferation, migration, and invasion of cells by activating glutamate metabotropic receptor 3
(GRM3) expression [219], which is a glutamate receptor modulating glutamate processing
and has been shown to drive breast cancer cell metastasis [244].
5. Conclusions and Future Perspectives
Environmental and occupational exposure to heavy metals, such as Cr(VI), Ni, and Cd,
remain serious public health concerns that harm hundreds of millions of people globally,
causing diseases and cancers in the digestive, respiratory, and urinary systems. Therefore,
a complete understanding of the mechanisms of metal carcinogenesis is important in
preventing and treating heavy metal-induced cancers. In recent years, a growing number
of studies have shown that short- or long-term exposure to Cr(VI), Ni, or Cd caused global
changes in epigenetic modifications and non-coding RNA expression in cells. Epigenetic
modifications and non-coding RNAs are important regulators of gene expression and have
been recognized as important players in tumor formation, development, and metastasis.
The currently available findings from studies discussed in this review indicate that altered
epigenetic modifications and dysregulated expression of non-coding RNAs (particularly
miRNA) are critically involved in metal carcinogen-induced cell malignant transformation,
tumorigenesis, and angiogenesis. Notably, although the number of studies is fast growing
over the past decade, only a small part of the hundreds of epigenetic changes and altered
non-coding RNAs from heavy metal exposure has been characterized and the significance
of most of these changes is still unknown. Therefore, to support the diagnosis and treatment
of human cancers resulting from metal carcinogen exposure, further studies are required to
better define the role of epigenetic modifications and miRNA in heavy metal carcinogenesis
and angiogenesis.
We should also acknowledge the limits of the current studies. Firstly, most studies
were carried out in cultured cells, such as 16HEBs and BEAS-2B cells, or xenograft models
based on transformed cells, which may not fully reflect the roles of epigenetic modifications
and non-coding RNAs in heavy metal exposure-induced cancers in vivo. More studies
using animal models such as mice and rats need to be performed to further reveal the
important role of dysregulation of epigenetic modifications and non-coding RNA in metal
carcinogenesis. Second, most of the knowledge about the roles of certain epigenetic markers
or non-coding RNAs is based on altering their levels in cells already transformed by
metal carcinogens to investigate the changes in malignant phenotypes. However, fewer
studies have been performed to investigate non-transformed cells to investigate if they
are able to prevent or promote metal-induced cell transformation. More studies based
on non-transformed cells or genetically modified animal models should be performed
to more accurately reveal the roles of dysregulated epigenetic marks and non-coding
RNAs in metal carcinogen-caused tumorigenesis. Finally, the knowledge of the roles
of epigenetic modifications and non-coding RNAs in metal carcinogen-induced cancer
should be translated into clinical work. More studies in animals and humans are needed to
evaluate their roles as biomarkers for early diagnosis and to develop preventive methods
and treatment options for metal carcinogen exposure-induced human cancers in the future.
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